Staff Profile

Introduction

Prof Quentin M. Anstee is Pro-Vice-Chancellor of the Faculty of Medical Sciences. He holds the Ruth & Lionel Jacobson Chair in Personalised Medicine and is also an Honorary Consultant Hepatologist in the Liver Unit at the Freeman Hospital, Newcastle.

His translational research has made major contributions across the pathophysiology, natural history, diagnosis and treatment of Metabolic-dysfunction Associated Steatotic Liver Disease (MASLD), formerly called Non-Alcoholic Fatty Liver Disease (NAFLD). His work has provided key insights into temporal changes in steatohepatitis during disease evolution, identified genetic and epigenetic modifiers of liver disease progression and hepatocellular carcinoma risk, and has substantially advanced the field of biomarker development in liver disease. He has coordinated several major international research consortia studying pathogenesis and developing/validating accurate biomarkers to assist the diagnosis, risk-stratification and monitoring of patients with MASLD including: ‘EPoS’ Elucidating Pathways of Steatohepatitis (EU H2020 funded €6 million, 2015-2019) and ‘LITMUS’ Liver Investigation: Testing Marker Utility in Steatohepatitis (EU IMI2 funded €47.3 million, 2017-2024). He leads the European MASLD Registry and is the chief investigator of multiple ongoing clinical trials assessing new medical therapies for MASLD. He is an NIHR Senior Investigator and has been named as one of the world’s most influential researchers in the Web of Science list of Highly Cited Researchers, amongst the top 1% of scientists by citation metrics. He is an Associate Editor of the Journal of Hepatology. 

Clinical Expertise

Prof Anstee's clinical practice is based in the Regional Liver Unit at the Freeman Hospital. His particular specialist interest is the diagnosis and treatment of Metabolic-dysfunction Associated Steatotic Liver Disease (MASLD), an increasingly common, progressive liver disease that is strongly associated with features of the 'metabolic syndrome' (including obesity, type 2 diabetes mellitus and dyslipidaemia). He established the regional MASLD specialist clinical service based at the Freeman Hospital, Newcastle.

He trained in medicine at University College London where he was awarded First Prize in Medicine in the final MB BS examination (The Philip Seth Belasco & Douglas Cree Prize, 1997). His post-graduate specialist clinical training in Hepatology/Gastroenterology & General Medicine was undertaken at hospitals in North-West London. Prior to moving his research group to Newcastle in 2010, he worked as Clinical Lecturer in Medicine & Hepatology at Imperial College London and St Mary's Hospital from 2007-2010.

He has expertise in the management of patients with a range of acute and chronic liver conditions including:

• Metabolic-dysfunction Associated Steatotic Liver Disease (MASLD) and Metabolic-dysfunction Associated Steatohepatitis (MASH), formerly called Non-Alcoholic Fatty Liver Disease (NAFLD).
• Alcoholic Liver Disease
• Chronic Viral Hepatitis
• Autoimmune hepatitis, PSC & PBC
• Cirrhosis and Portal hypertension
• Liver Transplantation

Qualifications

• BSc(Hons) - 1st Class 'Cell Pathology & Basic Medical Sciences', UCL (1994)
• MB BS with Distinction in Medicine, UCL (1997)
• MRCP(UK), Royal College of Physicians (London, 2000)
• PhD, Imperial College London (2007)
• FRCP, Fellow of the Royal College of Physicians (London, 2016)

Fellowships & Memberships of Learned Societies

• Fellow of the Royal College of Physicians (FRCP)
• Fellow of the Association of Physicians of Great Britain & Ireland (FAoP)
• Member of the British Association for the Study of the Liver, BASL
• Member of the British Society of Gastroenterology, BSG
• Member of the European Association for the Study of the Liver, EASL
• Member of the American Association for the Study of the Liver, AASLD

Research Interests

Prof Anstee's translational research has extended from the bench to the bedside with particular focus on the pathogenesis, diagnosis and treatment of Metabolic-dysfunction Associated Steatotic Liver Disease (MASLD) and its complications, including Cirrhosis and Hepatocellular Carcinoma (HCC).

Prof Anstee leads the European SLD (MASLD) Registry and was also a member of the EU FP7 funded FLIP: Fatty Liver - Inhibition of Progression consortium. He has coordinated a number of major international research consortia, each addressing different aspects of translational research in MASLD and its sequelae:

1. EPoS: Elucidating Pathways of Steatohepatitis is funded by the EU Horizon 2020 scheme (€6 million, 2015-2019). This consortium focuses on understanding the pathophysiology of MASLD and examining the determinants of individual risk for disease progression using a translational-science "multi-omics" approach.
2. LITMUS: Liver Investigation - Testing Marker Utility in Steatohepatitis is funded by the EU Investigative Medicines Initiative (IMI2) scheme (€47.3 million, 2017-2024). This consortium focuses on the comprehensive and robust validation/qualification of blood-based and imaging-based non-invasive biomarkers that may be used to diagnose and risk-stratify severity of MASLD. Ultimately, this will facilitate clinical trials for MASLD and improve the care of patients with MASLD by streamlining their diagnosis and management.
3. NASH-DTA/ADVANCE (£20 million, 2022 to date). This consortium leverages the latest advances in integrative multi-omics technologies to study the pathophysiology of cirrhosis and its downstream complications including hepatic decompensation and HCC.

Through these and other projects he has established many ongoing fruitful collaborations with academic researchers based in the UK and in numerous international universities and with industrial partners from the pharmaceutical and biomarker industries. He is chief investigator of multiple ongoing clinical trials assessing new medical therapies for MASLD.

Funding

Prof Anstee's research is supported by substantial research grant funding from the European Union (FP7, H2020, IMI2, Horizon Europe & IHI), the Medical Research Council (MRC) and the National Institute of Health Research (NIHR). He has also received grant funding from the Wellcome Trust, Academy of Medical Sciences and Industry. He has previously been awarded a HEFCE Clinical Senior Lecturer Award and an MRC Clinical Research Fellowship.

Undergraduate Teaching

• Medicine & Surgery MB BS Course (CSIM3): Lecturer
• Medicine & Surgery MB BS Course (NME2): Seminar Tutor
• Biomedical Sciences BSc Course (BMS3020 - Chronic Disease): Lecturer
• Biomedical Sciences BSc Course (BGM3061 - Integrated Genetics): Lecturer
• MB BS Undergraduate Tutor

Lecture topics have included: 'Metabolic-dysfunction Associated Steatotic Liver Disease (MASLD)', 'Alcoholic Liver Disease', 'Cirrhosis & its Complications', 'Genetics of MASLD'.

Postgraduate Teaching 

• Medical Sciences MRes project supervisor
• MRes (Diabetes): Lecturer
• MClinRes (MCR8006: Designing a Research Proposal): Lecturer
• MClinRes (MCR8004: Developing Your Career in Clinical Research): Lecturer

• Articles

  • Vali Y, van Dijk A-M, Lee J, Boursier J, Ratziu V, Yunis C, Schattenberg JM, Valenti L, Gomez MR, Schuppan D, Petta S, Allison M, Hartman ML, Porthan K, Dufour J-F, Bugianesi E, Gastadelli A, Derdak Z, Fournier-Poizat C, Shumbayawonda E, Kalutkiewicz M, Yki-Jarvinen H, Ekstedt M, Geier A, Trylesinski A, Francque S, Brass C, Pavlides M, Holleboom AG, Nieuwdorp M, Anstee QM, Bossuyt PM. Precision in Liver Diagnosis: Varied Accuracy Across Subgroups and the Need for Variable Thresholds in Diagnosis of MASLD. Liver International 2025, 45(2), e16240.
  • Doward LC, Breckons M, Balp M-M, Twiss J, Vale L, McSweeney L, Brass CA, Anstee QM, Sanyal AJ. NASH-CHECK patient-reported outcome instrument: evaluation of content and face validity for patients with metabolic dysfunction–associated steatohepatitis and compensated cirrhosis. Journal of Patient-Reported Outcomes 2025, 9(1), 76.
  • Jara M, Norlin J, Skalshøi Kjær M, Almholt K, Bendtsen KM, Bugianesi E, Cusi K, Galsgaard ED, Geybels M, Gluud LL, Harder LM, Loomba R, Mazzoni G, Newsome PN, Nitze LN, Palle MS, Ratziu V, Sejling A, Wong V, Anstee QM, Knudsen LB. Modulation of metabolic, inflammatory, and fibrotic pathways by Semaglutide in MASLD. Nature Medicine 2025, Epub ahead of print.
  • Schneider CV, Gross S, Balasubramani S, Tomanova P, Schrader C, Fromme M, Mandorfer M, Guldiken N, Schneider KM, Lurje G, Raptis A, Huang HYR, Mueller S, Reiberger T, Nahon P, Anstee QM, Daly AK, Govaere O, Strnad P. Insulin-like Growth Factor-1 Reflects Liver Disease Stage and Improves Prediction of Liver-related Mortality. Clinical Gastroenterology and Hepatology 2025, Epub ahead of print.
  • Wong VM, Amin NB, Takahashi H, Darekar A, Tacke F, Kiszko J, Rodriguez H, Nakajima A, Alkhouri N, Charlton M, Anstee QM. Efficacy and safety of ervogastat alone and in combination with clesacostat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) and F2–F3 fibrosis: results from the phase 2, randomised, double-blind MIRNA study. Lancet Gastroenterology & Hepatology 2025. In Press.
  • Younossi ZM, Razavi H, Sherman M, Allen AM, Anstee QM, Cusi K, Friedman SL, Lawitz E, Lazarus JV, Schuppan D, Romero-Gomez M, Schattenberg JM, Vos MB, Wong VW-S, Ratziu V, Hompesch M, Sanyal AJ, Loomba R. Addressing the High and Rising Global Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors' Perspective. Alimentary Pharmacology and Therapeutics 2025, 61(9), 1467-1478.
  • Sanyal AJ, Loomba R, Anstee QM, Ratziu V, Kowdley KV, Rinella ME, Harrison SA, Resnick MB, Capozza T, Sawhney S, Shelat N, Younossi ZM. Utility of pathologist panels for achieving consensus in NASH histologic scoring in clinical trials: Data from a phase 3 study. Hepatology Communications 2024, 8(1), e0325.
  • Armandi A, Sanavia T, Younes R, Caviglia GP, Rosso C, Govaere O, Liguori A, Francione P, Gallego-Duran R, Ampuero J, Pennisi G, Aller R, Tiniakos D, Burt A, David E, Vecchio F, Maggioni M, Cabibi D, McLeod D, Pareja MJ, Zaki MYW, Grieco A, Stal P, Kechagias S, Fracanzani AL, Valenti L, Miele L, Fariselli P, Eslam M, Petta S, Hagstrom H, George J, Schattenberg JM, Romero-Gomez M, Anstee QM, Bugianesi E. Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver disease. Gut 2024, 73(5), 825-834.
  • Anstee QM, Berentzen TL, Nitze LM, Jara M, Jensen AB, Kjær MS, Mangla KK, Tarp JM, Khunti K. Prognostic utility of Fibrosis-4 Index for risk of subsequent liver and cardiovascular events, and all-cause mortality in individuals with obesity and/or type 2 diabetes: a longitudinal cohort study. Lancet Regional Health - Europe 2024, 36, 100780.
  • Govaere O, Cockell SJ, Zatorska M, Wonders K, Tiniakos D, Frey AM, Palmowksi P, Walker R, Porter A, Trost M, Anstee QM, Daly AK. Pharmacogene expression during progression of metabolic dysfunction-associated steatotic liver disease: Studies on mRNA and protein levels and their relevance to drug treatment. Biochemical Pharmacology 2024, 228, 116249.
  • Ratziu V, Harrison SA, Hajji Y, Magnanensi J, Petit S, Majd Z, Delecroix E, Rosenquist C, Hum D, Staels B, Anstee QM, Sanyal AJ. NIS2+^TM as a screening tool to optimize patient selection in metabolic dysfunction-associated steatohepatitis clinical trials. Journal of Hepatology 2024, 80(2), 209-219.
  • Sena E, Tacke F, Anstee QM, Di Prospero N, Skalshoi- Kjaer M, Munoz-Martinez S, Rivera-Esteban J, Jimenez-Masip A, Banales JM, Martinez-Gomez M, Koenig F, Genesca J, Ratziu V, Pericas JM. Needs assessment for creation of a platform trial network in metabolic-dysfunction associated steatohepatitis. Communications Medicine 2024, 4(1), 144.
  • McTeer M, Applegate D, Mesenbrink P, Ratziu V, Schattenberg JM, Bugianesi E, Geier A, Gomez MR, Dufour J-F, Ekstedt M, Francque S, Yki-Jarvinen H, Allison M, Valenti L, Miele L, Pavlides M, Cobbold J, Papatheodoridis G, Holleboom AG, Tiniakos D, Brass C, Anstee QM, Missier P. Machine learning approaches to enhance diagnosis and staging of patients with MASLD using routinely available clinical information. PLoS ONE 2024, 19(2), e0299487.
  • Anstee QM, Magnanensi J, Hajji Y, Caron A, Majd Z, Rosenquist C, Hum DW, Staels B, Connelly MA, Loomba R, Harrison SA, Ratziu V, Sanyal AJ. Impact of age on NIS2+™ and other non-invasive blood tests for the evaluation of liver disease and detection of at-risk MASH. JHEP Reports 2024, 6(4), 101011.
  • McPherson S, Dyson JK, Jopson L, Masson S, Patel P, Anstee QM. How effective are experienced hepatologists at staging fibrosis using non-invasive fibrosis tests in patients with metabolic dysfunction-associated steatotic liver disease?. Alimentary Pharmacology and Therapeutics 2024, 60(2), 267-273.
  • Sabatini S, Sen P, Carli F, Pezzica S, Rosso C, Lembo E, Verrastro O, Daly A, Govaere O, Cockell S, Hyotylainen T, Mingrone G, Bugianesi E, Anstee QM, Oresic M, Gastaldelli A. Hepatic glucose production rises with the histological severity of metabolic dysfunction-associated steatohepatitis. Cell Reports Medicine 2024, 5(11), 101820.
  • Funuyet-Salas J, Martin-Rodriguez A, Perez-San-Gregorio MA, Vale L, Robinson T, Anstee QM, Romero-Gomez M. Health-related quality of life in non-alcoholic fatty liver disease: A cross-cultural study between Spain and the United Kingdom. PLoS ONE 2024, 19(5), e0300362.
  • McTeer M, Henderson R, Anstee QM, Missier P. Handling Overlapping Asymmetric Data Sets—A Twice Penalized P-Spline Approach. Mathematics 2024, 12(5), 777.
  • Mozes FE, Lee JA, Vali Y, Selvaraj EA, Jayaswal ANA, Boursier J, de Ledinghen V, Lupsor-Platon M, Yilmaz Y, Chan W-K, Mahadeva S, Karlas T, Wiegand J, Shalimar, Tsochatzis E, Liguori A, Wong VW-S, Lee DH, Holleboom AG, van Dijk A-M, Mak AL, Hagstrom H, Akbari C, Hirooka M, Lee DH, Kim W, Okanoue T, Shima T, Nakajima A, Yoneda M, Thuluvath PJ, Li F, Berzigotti A, Mendoza YP, Noureddin M, Truong E, Fournier-Poizat C, Geier A, Tuthill T, Yunis C, Anstee QM, Harrison SA, Bossuyt PM, Pavlides M. Diagnostic accuracy of non-invasive tests to screen for at-risk MASH—An individual participant data meta-analysis. Liver International 2024, 44(8), 1872-1885.
  • Harrison SA, Ratziu V, Anstee QM, Noureddin M, Sanyal AJ, Schattenberg JM, Bedossa P, Bashir MR, Schneider D, Taub R, Bansal M, Kowdley KV, Younossi Z, Loomba R. Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis. Alimentary Pharmacology and Therapeutics 2024, 59(1), 51-63.
  • Pulaski H, Harrison SA, Mehta SS, Sanyal AJ, Vitali MC, Manigat LC, Hou H, Madasu Christudoss SP, Hoffman SM, Stanford-Moore A, Egger R, Glickman J, Resnick M, Patel N, Taylor CE, Myers RP, Chung C, Patterson SD, Sejling A-S, Minnich A, Baxi V, Subramaniam GM, Anstee QM, Loomba R, Ratziu V, Montalto MC, Anderson NP, Beck AH, Wack KE. Clinical validation of an AI-based pathology tool for scoring of metabolic dysfunction-associated steatohepatitis. Nature Medicine 2024, 31, 315-322.
  • Anstee QM, Neuschwander-Tetri BA, Wai-Sun Wong V, Abdelmalek MF, Rodriguez-Araujo G, Landgren H, Park GS, Bedossa P, Alkhouri N, Tacke F, Sanyal AJ. Cenicriviroc Lacked Efficacy to Treat Liver Fibrosis in Nonalcoholic Steatohepatitis: AURORA Phase III Randomized Study. Clinical Gastroenterology and Hepatology 2024, 22(1), 124-134.e1.
  • Vacca V, Kamzolas I, Mørch Harder L, Oakley F, Trautwein C, Hatting M, Ross T, Bernardo B, Oldenburger A, Toftegaard Hjuler S, Ksiazek I, Linden D, Schuppan D, Rodriguez-Cuenca S, Manuela Tonini M, Castañeda TR, Kannt A, Rodrigues CMP, Cockell S, Govaere O, Daly AK, Allison M, Honnens de Lichtenberg K, Kim YO, Lindblom A, Oldam S, Andréasson A-C, Schlerman F, Marioneaux J, Sanyal A, Afonso MB, Younes R, Amano Y, Friedman SL, Wang S, Bhattacharya D, Simon E, Paradis V, Burt A, Grypari IM, Davies S, Driessen A, Yashiro H, Pors S, Worm Andersen M, Feigh M, Yunis C, Bedossa P, Stewart M, Cater HL, Wells S, Schattenberg JM, Anstee QM, The LITMUS Investigators, Tiniakos D, Perfield JW, Petsalaki E, Davidsen P, Vidal-Puig A. An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD). Nature Metabolism 2024, 6, 1178-1196.
  • Pericàs JM, Anstee QM, Augustin S, Bataller R, Berzigotti A, Ciudin A, Francque S, Abraldes JG, Hernández-Gea V, Pons M, Reiberger T, Rowe IA, Rydqvist P, Schabel E, Tacke F, Tsochatzis EA, Genescà J. A roadmap for clinical trials in MASH-related compensated cirrhosis. Nature Reviews Gastroenterology and Hepatology 2024, 21, 809–823.
  • Sanyal AJ, Bedossa P, Fraessdorf M, Neff GW, Lawitz E, Bugianesi E, Anstee QM, Ajaz Hussain S, Newsome PN, Ratziu V, Hosseini-Tabatabaei A, Schattenberg JM, Noureddin M, Alkhouri N, Younes R. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. New England Journal of Medicine 2024, 391(4), 311-319.
  • Twiss J, Whalley D, Doward L, Balp M-M, Brass CA, Cryer D, Sanyal A, Anstee QM. Validation of NASH-CHECK: a novel patient-reported outcome measure for nonalcoholic steatohepatitis. Journal of Patient-Reported Outcomes 2023, 7(1), 69.
  • Anstee QM, Lucas KJ, Francque S, Abdelmalek MF, Sanyal AJ, Ratziu V, Gadano AC, Rinella M, Charlton M, Loomba R, Mena E, Schattenberg JM, Noureddin M, Lazas D, Goh G, Sarin SK, Yilmaz Y, Martic M, Stringer R, Kochuparampil J, Chen L, Rodriguez-Araujo G, Chng E, Naoumov NV, Brass C, Pedrosa MC. Tropifexor plus cenicriviroc combination versus monotherapy in non-alcoholic steatohepatitis: Results from the Phase 2b TANDEM study. Hepatology 2023, 78(4), 1223-1239.
  • Ford BE, Chachra SS, Rodgers K, Moonira T, Al-Oanzi ZH, Anstee QM, Reeves HL, Schattenberg JM, Fairclough RJ, Smith DM, Tiniakos D, Agius L. The GCKR-P446L gene variant predisposes to raised blood cholesterol and lower blood glucose in the P446L mouse-a model for GCKR rs1260326. Molecular Metabolism 2023, 72, 101722.
  • McPherson S, Jarvis H, McGonigle J, Bedlington J, Dean J, Hallsworth K, Hanon E, Liddle T, Luvai A, Mansour D, Patel P, Renwick L, Teare D, Tanney C, Anstee Q. Stratification of LIver Disease (SOLID): Protocol for a prospective observational cohort study to determine the optimum biomarker strategies for the detection of advanced liver disease at the primary-secondary care interface. BMJ Open Gastroenterology 2023, 10(1), e001092.
  • Karsdal MA, Hallsworth K, Scragg J, Leeming DJ, Villesen IF, Avery L, Haigh L, Govaere O, Wichmann S, Taylor G, Cassidy S, McPherson S, Anstee QM. Serum levels of fibrogenesis biomarkers reveal distinct endotypes predictive of response to weight loss in advanced nonalcoholic fatty liver disease. Hepatology Communications 2023, 7(10), e0254.
  • Parker R, Allison M, Anderson S, Aspinall R, Bardell S, Bains V, Buchanan R, Corless L, Davidson I, Dundas P, Fernandez J, Forrest E, Forster E, Freshwater D, Gailer R, Goldin R, Hebditch V, Hood S, Jones A, Lavers V, Lindsay D, Maurice J, McDonagh J, Morgan S, Nurun T, Oldroyd C, Oxley E, Pannifex S, Parsons G, Phillips T, Rainford N, Rajoriya N, Richardson P, Ryan J, Sayer J, Smith M, Srivastava A, Stennett E, Towey J, Vaziri R, Webzell I, Wellstead A, Dhanda A, Masson S. Quality standards for the management of alcohol-related liver disease: Consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology ARLD special interest group. BMJ Open Gastroenterology 2023, 10(1), e001221.
  • Wong VW-S, Tak WY, Goh GBB, Cheng P-N, Lawitz EJ, Younossi ZM, Vuppalanchi R, Younes Z, Alkhouri N, Wang L, Liu J, Kersey K, Myers RP, Harrison SA, Goodman Z, Trauner M, Romero-Gomez M, Anstee QM, Nguyen MH, Okanoue T. Performance of Noninvasive Tests of Fibrosis Among Asians, Hispanic, and non-Hispanic Whites in the STELLAR Trials. Clinical Gastroenterology and Hepatology 2023, 21(1), 90-102.e6.
  • Mózes FE, Lee JA, Yasaman Vali, Osama Alzoubi, Anstee QM, Harrison SA, Pavlides M, Bossuyt PM, LITMUS investigators. Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis. The Lancet Gastroenterology & Hepatology 2023, 8(8), 704-713.
  • Harrison SA, Ratziu V, Magnanensi J, Hajji Y, Deledicque S, Majd Z, Rosenquist C, Hum DW, Staels B, Anstee QM, Sanyal AJ. NIS2+™, an optimisation of the blood-based biomarker NIS4® technology for the detection of at-risk NASH: A prospective derivation and validation study. Journal of Hepatology 2023, 79(3), 758-767.
  • Loomba R, Huang DQ, Sanyal AJ, Anstee QM, Trauner M, Lawitz EJ, Ding D, Ma L, Jia C, Billin A, Huss RS, Chung C, Goodman Z, Wong VW-S, Okanoue T, Romero-Gomez M, Abdelmalek MF, Muir A, Afdhal N, Bosch J, Harrison S, Younossi ZM, Myers RP. Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis. Gut 2023, 72(3), 581-589.
  • Rosso C, Caviglia GP, Birolo G, Armandi A, Pennisi G, Pelusi S, Younes R, Liguori A, Perez-Diaz-del-Campo N, Nicolosi A, Govaere O, Castelnuovo G, Olivero A, Abate ML, Ribaldone DG, Fariselli P, Valenti L, Miele L, Petta S, Romero-Gomez M, Anstee QM, Bugianesi E. Impact of PNPLA3 rs738409 Polymorphism on the Development of Liver-Related Events in Patients With Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology 2023, 21(13), P3314-3321.E3.
  • Wong VW-S, Anstee QM, Nitze LM, Geerts A, George J, Nolasco V, Kjaer MS, Ladelund S, Newsome PN, Ratziu V. FibroScan-aspartate aminotransferase (FAST) score for monitoring histological improvement in non-alcoholic steatohepatitis activity during semaglutide treatment: post-hoc analysis of a randomised, double-blind, placebo-controlled, phase 2b trial. eClinicalMedicine 2023, 66, 102310.
  • Jacobson IM, Wong VW-S, Castera L, Anstee QM, Noureddin M, Cusi K, Harrison SA, Bugianesi E, Younossi ZM. Expert Panel Consensus on Clinical Assertion Statements Describing Noninvasive Tools for Diagnosing Nonalcoholic Steatohepatitis. Journal of Clinical Gastroenterology 2023, 57(3), 253-264.
  • Lazarus JV, Mark HE, Villota-Rivas M, Palayew A, Carrieri P, Colombo M, Ekstedt M, Esmat G, George J, Marchesini G, Novak K, Ocama P, Ratziu V, Razavi H, Romero-Gómez M, Silva M, Spearman CW, Tacke F, Tsochatzis EA, Yilmaz Y, Younossi ZM, Wong VW, Zelber-Sagi S, Cortez-Pinto H, Anstee QM. The global NAFLD policy review and preparedness index: are countries ready to address this silent public health challenge?. Journal of Hepatology 2022, 76(4), 771-780.
  • Haigh L, Kirk C, El Gendy K, Gallacher J, Errington L, Mathers JC, Anstee QM. The effectiveness and acceptability of Mediterranean diet and calorie restriction in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis. Clinical Nutrition 2022, 41(9), 1913-1931.
  • Zaki MYW, Alhasan SF, Shukla R, McCain M, Laszczewska M, Geh D, Patman GL, Televantou D, Whitehead A, Mauricio JP, Barksby B, Gee LM, Paish HL, Leslie J, Younes R, Burt AD, Borthwick LA, Thomas H, Beale GS, Govaere O, Sia D, Anstee QM, Tiniakos D, Oakley F, Reeves HL. Sulfatase-2 from Cancer Associated Fibroblasts: An Environmental Target for Hepatocellular Carcinoma?. Liver Cancer 2022, 11(6), 540-557.
  • Pai RK, Jairath V, Hogan M, Zou G, Adeyi OA, Anstee QM, Aqel BA, Behling C, Carey EJ, Clouston AD, Corey K, Feagan BG, Kleiner DE, Ma C, McFarlane SC, Noureddin M, Ratziu V, Valasek MA, Younossi ZM, Harrison SA, Loomba R. Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score. Hepatology 2022, 76(4), 1150-1163.
  • Anstee QM, Hallsworth K, Lynch N, Hauvespre A, Mansour E, Kozma S, Marino J-P, Bottomley J, Piercy J, Higgins V. Real-world management of non-alcoholic steatohepatitis differs from clinical practice guideline recommendations and across regions. JHEP Reports 2022, 4(1), 100411.
  • Sen P, Govaere O, Sinioja T, McGlinchey A, Geng D, Ratziu V, Bugianesi E, Schattenberg JM, Vidal-Puig A, Allison M, Cockell S, Daly AK, Hyotylainen T, Anstee QM, Oresic M. Quantitative modeling of human liver reveals dysregulation of glycosphingolipid pathways in nonalcoholic fatty liver disease. iScience 2022, 25(9), 104949.
  • McPherson S, Armstrong MJ, Cobbold JF, Corless L, Anstee QM, Aspinall RJ, Barclay ST, Brennan PN, Cacciottolo TM, Goldin RD, Hallsworth K, Hebditch V, Jack K, Jarvis H, Johnson J, Li W, Mansour D, McCallum M, Mukhopadhya A, Parker R, Ross V, Rowe IA, Srivastava A, Thiagarajan P, Thompson AI, Tomlinson J, Tsochatzis EA, Yeoman A, Alazawi W. Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group. Lancet Gastroenterology and Hepatology 2022, 7(8), 755-769.
  • Tingle SJ, Thompson ER, Bates L, Ibrahim IK, Govaere O, Shuttleworth V, Wang L, Figueiredo R, Palmer J, Bury Y, Anstee QM, Wilson C. Pharmacological testing of therapeutics using normothermic machine perfusion: A pilot study of 2,4-dinitrophenol delivery to steatotic human livers. Artificial Organs 2022, 46(11), 2201-2214.
  • Rinella M, Dufour JF, Anstee QM, Goodman Z, Younossi Z, Harrison SA, Loomba R, Sanyal AJ, Bonacci M, Trylesinski A, Natha M, Shringarpure R, Granston T, Venugopal A, Ratziu R. Noninvasive Evaluation of Response to Obeticholic Acid in Patients with NASH: Results from the REGENERATE Study. Journal of Hepatology 2022, 76(3), 536-548.
  • Martinez-Arranz I, Bruzzone C, Noureddin M, Gil-Redondo R, Minchole I, Bizkarguenaga M, Arretxe E, Iruarrizaga-Lejarreta M, Fernandez-Ramos D, Lopitz-Otsoa F, Mayo R, Embade N, Newberry E, Mittendorf B, Izquierdo-Sanchez L, Smid V, Arnold J, Iruzubieta P, Perez Castano Y, Krawczyk M, Marigorta UM, Morrison MC, Kleemann R, Martin-Duce A, Hayardeny L, Vitek L, Bruha R, Aller de la Fuente R, Crespo J, Romero-Gomez M, Banales JM, Arrese M, Cusi K, Bugianesi E, Klein S, Lu SC, Anstee QM, Millet O, Davidson NO, Alonso C, Mato JM. Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles. Hepatology 2022, 76(4), 1121-1134.
  • Martínez-Arranz I, Bruzzone C, Noureddin M, Gil-Redondo R, Minchole I, Bizkarguenaga M, Arretxe E, Iruarrizaga-Lejarreta M, Fernandez-Ramos D, Lopitz-Otsoa F, Mayo R, Embade N, Newberry E, Mittendorf B, Izquierdo-Sanchez L, Smid V, Arnold J, Iruzubieta P, Castano YP, Krawczyk M, Marigorta UM, Morrison MC, Kleemann R, Martin-Duce A, Hayardeny L, Vitek L, Bruha R, AllerdelaFuente R, Crespo J, Romero-Gomez M, Banales JM, Arrese M, Cusi K, Bugianesi E, Klein S, Lu SC, Anstee QM, Millet O, Davidson NO, Alonso C, Mato JM. Metabolic subtypes of nonalcoholic fatty liver disease patients exhibit distinctive cardiovascular risk profiles. Hepatology 2022, 76(4), 1121-1134.
  • McGlinchey AJ, Govaere O, Geng D, Ratziu V, Allison M, Bousier J, Petta S, deOliviera C, Bugianesi E, Schattenberg JM, Daly AK, Hyotylainen T, Anstee QM, Oresic M. Metabolic signatures across the full spectrum of nonalcoholic fatty liver disease. JHEP Reports 2022, 4(5), 100477.
  • Govaere O, Petersen SK, Martinez-Lopez N, Wouters J, VanHaele M, Mancina RM, Jamialahmadi O, Bilkei-Gorzo O, Lassen PB, Darlay R, Peltier J, Palmer JM, Younes R, Tiniakos D, Aithal GP, Allison M, Vacca M, Göransson M, Berlinguer-Palmini R, Clark J, Drinnan MJ, Yki-Järvinen H, Dufour JF, Ekstedt M, Francque S, Petta S, Bugianesi E, Schattenberg JM, Day CP, Cordell HJ, Topal B, Clément K, Romeo S, Ratziu V, Roskams T, Daly AK, Anstee QM, Trost M, Härtlova A. Macrophage Scavenger Receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease. Journal of Hepatology 2022, 76(5), 1001-1012.
  • Johnson K, Leary PJ, Govaere O, Barter MJ, Charlton SH, Cockell SJ, Tiniakos D, Zatorska M, Bedossa P, Brosnan MJ, Cobbold JF, Ekstedt M, Aithal GP, Clement K, Schattenberg JM, Boursier J, Ratziu V, Bugianesi E, Anstee QM, Daly AK, LITMUS Consortium Investigators. Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance. JHEP Reports 2022, 4(2), 100409.
  • Amin NB, Darekar A, Anstee QM, Wong VW-S, Tacke F, Vourvahis M, Lee DS, Charlton M, Alkhouri N, Nakajima A, Yunis C. Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) study. BMJ Open 2022, 12(3), e056159.
  • Mozes FE, Lee JA, Selvaraj EA, Jayaswal ANA, Trauner M, Boursier J, Fournier C, Staufer K, Stauber RE, Bugianesi E, Younes R, Gaia S, Lupsor-Platon M, Petta S, Shima T, Okanoue T, Mahadeva S, Chan W, Eddowes PJ, Newsome PN, Wong VW, deLedinghen V, Fan J, Shen F, Cobbold JF, Sumida Y, Okajima A, Schattenberg JM, Labenz C, Kim W, Lee MS, Wiegand J, Karlas T, Yilmaz Y, Aithal GP, Palaniyappan N, Cassinotto C, Aggarwal S, Garg H, Ooi G, Nakajima A, Yoneda M, Zio M, Barget N, Geier A, Tuthill T, Brosnan JM, Anstee QM, Neubauer S, Harrison SA, Bossuyt PM, Pavlides M. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD – An individual patient data meta-analysis. Gut 2022, 71(5), 1006-1019.
  • Labenz C, Toenges G, Zheng M-H, Ding D, Myers RP, Galle PR, Armandi A, Ampuero J, Gomez MR, Bugianesi E, Anstee QM, Schattenberg JM. Derivation and validation of the NAFLD Cirrhosis Score (NCS) to distinguish bridging fibrosis from cirrhosis. European Journal of Internal Medicine 2022, 98, 53-60.
  • Sebastiani G, Patel K, Ratziu V, Feld JJ, Neuschwander-Tetri BA, Pinzani M, Petta S, Berzigotti A, Metrakos P, Shoukry N, Brunt EM, Tang A, Cobbold JF, Ekoe J-M, Seto K, Ghali P, Chevalier S, Anstee QM, Watson H, Bajaj H, Stone J, Swain MG, Ramji A. Current considerations for clinical management and care of non-alcoholic fatty liver disease: Insights from the 1st International Workshop of the Canadian NASH Network (CanNASH). Canadian Liver Journal 2022, 5(1), 61-90.
  • Geh D, Watson R, Sen G, French JJ, Hammond J, Turner P, Hoare T, Anderson K, Mcneil M, Mcpherson S, Masson S, Dyson J, Donnelly M, Macdougal L, Patel P, Hudson M, Anstee QM, White S, Robinson S, Pandanaboyana S, Walker L, Mccain M, Bury Y, Raman S, Burt A, Parkinson D, Haugk B, Darne A, Wadd N, Asghar S, Mariappan L, Margetts J, Stenberg B, Scott J, Littler P, Manas DM, Reeves HL. COVID-19 and liver cancer: Lost patients and larger tumours. BMJ Open Gastroenterology 2022, 9(1), e000794.
  • Brunt EM, Clouston AD, Goodman Z, Guy C, Kleiner DE, Lackner C, Tiniakos DG, Wee A, Yeh M, Leow WQ, Chng E, Ren Y, Bee G, Powell EE, Rinella M, Sanyal AJ, Neuschwander-Tetri B, Younossi Z, Charlton M, Ratziu V, Harriso SA, Tai D, Anstee QM. Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD. Journal of Hepatology 2022, 76(5), 1030-1041.
  • Vali Y, Eijk R, Hicks T, Jones WS, Suklan J, Holleboom AG, Ratziu V, Langendam MW, Anstee QM, Bossuyt PMM. Clinicians’ Perspectives on Barriers and Facilitators for the Adoption of Non-Invasive Liver Tests for NAFLD: A Mixed-Method Study. Journal of Clinical Medicine 2022, 11(10), 2707.
  • Younes R, Govaere O, Petta S, Miele L, Tiniakos D, Burt A, David E, Vecchio FM, Maggioni M, Cabibi D, McLeod D, Pareja MJ, Fracanzani AL, Aller R, Rosso C, Ampuero J, Gallego-Duran R, Armandi A, Caviglia GP, Zaki MYW, Liguori A, Francione P, Pennisi G, Grieco A, Birolo G, Fariselli P, Eslam M, Valenti L, George J, Romero-Gomez M, Anstee QM, Bugianesi E. Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?. Gut 2022, 71(2), 382-390.
  • Ratziu V, Anstee QM, Wong VW-S, Schattenberg JM, Bugianesi E, Augustin S, Gheorghe L, Zambon V, Reau N. An international survey on patterns of practice in NAFLD and expectations for therapies—The POP-NEXT project. Hepatology 2022, 76(6), 1766-1777.
  • Gallage S, Avila JEB, Ramadori P, Focaccia E, Rahbari M, Ali A, Malek NP, Anstee QM, Heikenwalder M. A researcher’s guide to preclinical mouse NASH models. Nature Metabolism 2022, 4, 1632-1649.
  • Vujkovic M, Ramdas S, Lorenz KM, Guo X, Darlay R, Cordell HJ, He J, Gindin Y, Chung C, Myers R, Schneider C, Park J, Lee K, Serper M, Carr R, Kaplan D, Haas M, MacLean M, Witschey W, Zhu X, Tcheandjieu C, Kember R, Kranzler H, Verma A, Giri A, Klarin D, Sun Y, Huang J, Huffman J, Townsend Creasy K, Hand N, Liu C, Long M, Yao J, Budoff M, Tan J, Li X, Lin H, Chen Y, Taylor K, Chang R, Krauss R, Vilarinho S, Brancale J, Nielsen J, Locke A, Jones M, Verweij N, Baras A, Reddy K, Neuschwander-Tetri B, Schwimmer J, Sanyal A, Chalasani N, Ryan K, Mitchell B, Gill D, Wells A, Manduchi E, Saiman Y, Mahmud N, Miller D, Reaven P, Phillips L, Muralidhar S, DuVall S, Lee J, Assimes T, Pyarajan S, Cho K, Edwards T, Damrauer S, Wilson P, Gaziano J, ODonnell C, Khera A, Grant S, Brown C, Tsao P, Saleheen D, Lotta L, Bastarache L, Anstee QM, Daly A, Meigs J, Rotter JI, Lynch JA, Rader DJ, Voight BF, Chang KM. A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation. Nature Genetics 2022, 54, 761-771.
  • Kozumi K, Kodama T, Murai H, Sakane S, Govaere O, Cockell S, Motooka D, Kakita N, Yamada Y, Kondo Y, Tahata Y, Yamada R, Hikita H, Sakamori R, Kamada Y, Daly AK, Anstee QM, Tatsumi T, Morii E, Takehara T. Transcriptomics Identify Thrombospondin-2 as a Biomarker for Nonalcoholic Steatohepatitis and Advanced Liver Fibrosis. Hepatology 2021, 74(5), 2452-2466.
  • Jarvis H, McPherson S, Anstee QM, Hanratty B. The pathway to better primary care for chronic liver disease. British Journal of General Practice 2021, 71(705), 180-182.
  • Lazarus JV, Palayew A, Carrieri P, Ekstedt M, Marchesini G, Novak K, Ratziu V, Romero-Gómez M, Tacke F, Zelber-Sagi S, Cortez-Pinto H, Anstee QM. The European ‘NAFLD Preparedness Index’ — is Europe ready to meet the challenge of fatty liver disease?. JHEP Reports 2021, 3(2), 100234.
  • Younossi ZM, Anstee QM, Wong VW, Trauner M, Lawitz EJ, Harrison SA, Camargo M, Kersey K, Subramanian GM, Myers RP, Stepanova M. The Association of Histologic and Non-invasive Tests with Adverse Clinical and Patient-Reported Outcomes in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis. Gastroenterology 2021, 160(5), 1608-1619.e13.
  • Teo K, Abeysekera KWM, Adams L, Aigner E, Anstee QM, Banales JM, Banerjee R, Basu P, Berg T, Bhatnagar P, Buch S, Canbay A, Caprio S, Chatterjee A, Chen YD, Chowdhury A, Daly AK, Datz C, deGraciaHahn D, DiStefano JK, Dong J, Duret A, Emdin C, Fairey M, Gerhard GS, Guo X, Hampe J, Hickman M, Heintz L, Hudert C, Hunter H, Kelly M, Kozlitina J, Krawczyk M, Lammert F, Langenberg C, Lavine J, Li L, Lim HK, Loomba R, Luukkonen PK, Melton PE, Mori TA, Palmer ND, Parisinos CA, Pillai SG, Qayyum F, Reichert MC, Romeo S, Rotter JI, Im YR, Santoro N, Schafmayer C, Speliotes EK, Stender S, Stickel F, Still CD, Strnad P, Taylor KD, TybjærgHansen A, Umano GR, Utukuri M, Valenti L, Wagenknecht LE, Wareham NJ, Watanabe RM, Wattacheril J, Yaghootkar H, YkiJarvinen H, Young KA, Mann JP. rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis. Journal of Hepatology 2021, 74(1), 20-30.
  • Lee J, Vali Y, Boursier J, Spijker R, Anstee QM, Bossuyt PM, Zafarmand H. Prognostic accuracy of FIB-4, NAFLD fibrosis score, and APRI for NAFLD-related events: a systematic review. Liver International 2021, 41(2), 261-270.
  • Haigh L, McPherson S, Mathers JC, Anstee QM. Nutrigenetics-based intervention approach for adults with non-alcoholic fatty liver disease (NAFLD): study protocol for a randomised controlled feasibility trial. BMJ Open 2021, 11, e045922.
  • Bianco C, Jamialahmadi O, Pelusi S, Baselli G, Dongiovanni P, Zanoni I, Santoro L, Maier S, Liguori A, Meroni M, Borroni V, DAmbrosio R, Spagnuolo R, Alisi A, Federico A, Bugianesi E, Petta S, Miele L, Vespasiani-Gentilucci U, Anstee QM, Stickel F, Hampe J, Fischer J, Berg T, Fracanzani AL, Soardo G, Reeves H, Prati D, Romeo S, Valenti L. Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. Journal of Hepatology 2021, 74(4), P775-782.
  • Pfister D, Gonzalo N, Nunez N, Pinyol R, Govaere O, Pinter M, Szydlowska M, Gupta R, Qiu M, Deczkowska A, Weiner A, Muller F, Sinha A, Friebel E, Engleitner T, Lenggenhager D, Moncsek A, Heide D, Stirm K, Kosla J, Kotsiliti E, Leone V, Dudek M, Yousuf S, Inverso D, Singh I, Teijeiro A, Castet F, Montironi C, Haber PK, Tiniakos D, Bedossa P, Cockell S, Younes R, Vacca M, Marra F, Schattenberg JM, Allison M, Bugianesi E, Ratziu R, Pressiani T, DAlessio A, Personeni N, Rimassa L, Daly AK, Scheiner B, Pomej K, Kirstein MM, Vogel A, PeckRadosavljevic M, Hucke F, Finkelmeier F, Waidmann O, Trojan J, Schulze K, Wege H, Koch S, Weinmann A, Bueter M, Rossler F, Siebenhuner A, DeDosso S, Mallm JP, Umansky V, Jugold M, Luedde T, Schietinger A, Schirmacher P, Emu B, Augustin HG, Billeter A, MullerStich B, Kikuchi H, Duda DG, Kutting F, Waldschmidt DT, Ebert MP, Rahbari N, Mei HE, Schulz AR, Ringelhan M, Malek N, Spahn S, Bitzer M, deGalarreta MR, Lujambio A, Dufour JF, Marron TU, Kaseb A, Kudo M, Huang YH, Djouder N, Wolter K, Zender L, Marche PN, Decaens T, Pinato DJ, Rad R, Mertens JC, Weber A, Unger K, Meissner F, Roth S, Jilkova ZM, Claassen M, Anstee QM, Amit I, Knolle P, Becher B, Llovet JM, Heikenwalder M. NASH limits anti-tumor surveillance in immunotherapy-treated HCC. Nature 2021, 592, 450-456.
  • Younes R, Caviglia GP, Govaere O, Rosso C, Armandi A, Sanavia T, Pennisi G, Liguori A, Francione P, Gallego-Duran R, Ampuero J, Garcia Blanco MJ, Aller R, Tiniakos D, Burt A, David E, Vecchio FM, Maggioni M, Cabibi D, Pareja MJ, Zaki MYW, Grieco A, Fracanzani AL, Valenti L, Miele L, Fariselli P, Petta S, Romero-Gomez M, Anstee QM, Bugianesi E. Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease. Journal of Hepatology 2021, 75(4), 786-794.
  • Hall Z, Chiarugi D, Charidemou E, Leslie J, Scott E, Pelligrinet L, Allison M, Mocciaro G, Anstee QM, Evan GI, Hoare M, VidalPuig A, Oakley F, Vacca M, Griffin JL. Lipid remodelling in hepatocyte proliferation and hepatocellular carcinoma . Hepatology 2021, 73(3), 1028-1044.
  • Zaki MYW, Mahdi AK, Patman GL, Whitehead A, Mauricio JP, McCain MV, Televantou D, Abou-Beih S, Ramon-Gil E, Watson R, Cox C, Leslie J, Wilson C, Govaere O, Lunec J, Mann DA, Nakjang S, Oakley F, Shukla R, Anstee QM, Tiniakos D, Reeves HL. Key features of the environment promoting liver cancer in the absence of cirrhosis. Scientific Reports 2021, 11(1), 16727.
  • Neilson LJ, MacDougall L, Lee PS, Hardy T, Beaton D, Chandrapalan S, Ebraheem A, Hussien M, Galbraith S, Looi S, Oxenburgh S, Phaw NA, Taylor W, Haigh L, Hallsworth K, Mansour D, Dyson JK, Masson S, Anstee Q, McPherson S. Implementation of a care bundle improves the management of patients with non-alcoholic fatty liver disease. Frontline Gastroenterology 2021, 12(7), 578-585.
  • Scragg J, Hallsworth K, Taylor G, Cassidy S, Haigh L, Boyle M, Anstee QM, McPherson S, Avery L. Factors associated with engagement and adherence to a low energy diet to promote 10% weight loss in patients with clinically significant non-alcoholic fatty liver disease. BMJ Open Gastroenterology 2021, 8(1), e000678.
  • Mansour D, Grapes A, Herscovitz M, Cassidy P, Vernazza J, Broad A, Anstee QM, McPherson S. Embedding assessment of liver fibrosis into routine diabetic review in primary care. JHEP Reports 2021, 3(4), 100293.
  • Hallsworth K, McPherson S, Anstee QM, Flynn D, Haigh L, Avery L. Digital Intervention with Lifestyle Coach Support to Target Dietary and Physical Activity Behaviors of Adults with Nonalcoholic Fatty Liver Disease: Systematic Development Process of VITALISE Using Intervention Mapping. Journal of Medical Internet Research 2021, 23(1), e20491.
  • Selvaraj EA, Mozes FE, Jayaswal AN, Zafarmand MH, Vali Y, Lee JA, Levick CK, Josephyoung LA, Palaniyappan N, Liu CH, Aithal GP, RomeroGomez M, Brosnan MJ, Tuthill TA, Anstee QM, Neubauer S, Harrison SA, Bossuyt PM, Pavlides M. Diagnostic Accuracy of Elastography and Magnetic Resonance Imaging in Patients with NAFLD: a systematic review and meta-analysis. Journal of Hepatology 2021, 75(4), 770-785.
  • Doward LC, Balp MM, Twiss J, Slota C, Cryer D, Brass CA, Anstee QM, Sanyal AJ. Development of a Patient-Reported Outcome Measure for Non-Alcoholic Steatohepatitis (NASH-CHECK): Results of a Qualitative Study. The Patient - Patient-Centered Outcomes Research 2021, 14, 533-543.
  • Petroff D, Blank V, Newsome PN, ShalimarVoican CS, Thiele M, deLedinghen V, Baumeler S, Chan WK, Perlemuter G, Cardoso AC, Aggarwal S, Sasso M, Eddowes PJ, Allison M, Tsochatzis E, Anstee QM, Sheridan D, Cobbold JF, Naveau S, Lupsor-Platon M, Mueller S, Krag A, Irles-Depe M, Semela D, Wong G, Wong VW, Villela-Nogueira CA, Garg H, Chazouilleres O, Wiegand J, Karlas T. Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis. The Lancet Gastroenterology & Hepatology 2021, 6(3), 185-198.
  • Eldafashi N, Darlay R, Shukla R, McCain MV, Watson R, Liu YL, McStraw N, Fathy M, Fawzy MA, Zaki MYW, Daly AK, Mauricio JP, Burt AD, Haugk B, Cordell HJ, Bianco C, Dufour J-F, Valenti L, Anstee QM, Reeves HL. A pdcd1 role in the genetic predisposition to nafld-hcc?. Cancers 2021, 13(6), 1412.
  • Bruzzone C, Gil-Redondo R, Seco M, Barragan R, de la Cruz L, Cannet C, Schafer H, Fang F, Diercks T, Bizkarguenaga M, Gonzalez-Valle B, Lain A, Sanz-Parra A, Coltell O, de Letona AL, Spraul M, Lu SC, Buguianesi E, Embade N, Anstee QM, Corella D, Mato JM, Millet O. A molecular signature for the metabolic syndrome by urine metabolomics. Cardiovascular Diabetology 2021, 20(1), 155.
  • Taylor-Weiner A, Pokkalla H, Han L, Jia C, Huss R, Chung C, Elliott H, Glass B, Pethia K, Carrasco-Zevallos O, Shukla C, Khettry U, Najarian R, Taliano R, Subramanian GM, Myers RP, Wapinski I, Khosla A, Resnick M, Montalto M, Anstee QM, Wong VW, Trauner M, Lawitz EJ, Harrison SA, Okanoue T, Romero-Gomez M, Goodman Z, Loomba R, Beck AH, Younossi ZM. A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH. Hepatology 2021, 741, 133-147.
  • Govaere O, Cockell S, Tiniakos D, Queen R, Younes R, Vacca M, Alexander L, Ravaioli F, Palmer J, Petta S, Boursier J, Rosso C, Johnson K, Wonders K, Day CP, Ekstedt M, Oresic M, Darlay R, Cordell H, Marra F, Vidal-Puig A, Bedossa P, Schattenberg JM, Clément K, Allison M, Bugianesi E, Ratziu V, Daly AK, Anstee QM. Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis. Science Translational Medicine 2020, 12(572), eaba4448.
  • Hardy T, Wonders K, Younes R, Aithal GP, Aller R, Allison M, Bedossa P, Betsou F, Boursier J, Brosnan MJ, Burt A, Cobbold J, Cortez-Pinto H, Day CP, Dufour JF, Ekstedt M, Francque S, Harrison S, Miele L, Nasr P, Papatheodoridis G, Petta S, Tiniakos D, Torstenson R, Valenti L, Holleboom AG, Yki-Jarvinen H, Geier A, Romero-Gomez M, Ratziu V, Bugianesi E, Schattenberg JM, Anstee QM, on behalf of the LITMUS Consortium. The European NAFLD Registry: a real-world longitudinal cohort study of nonalcoholic fatty liver disease. Contemporary Clinical Trials 2020, 98, 106175.
  • O'Hara J, Finnegan A, Dhillon H, Ruiz Casas L, Pedra G, Franks B, Morgan G, Hebditch V, Orman A, Jönsson B, Mabhala M, Reic T, VanThiel I, Ratziu V, Romero-Gomez M, Bugianesi E, Schattenberg JM, Anstee QM. The Cost of Non-Alcoholic Steatohepatitis (NASH) in Europe and USA: the GAIN Study. JHEP Reports 2020, 2(5), 100142.
  • Harrison SA, Wong V, Okanoue T, Bzowej N, Vuppalanchi R, Younes Z, Kohli A, Sarin S, Caldwell SH, Alkhouri N, Shiffman ML, Camargo M, Li G, Kersey K, Jia C, Zhu Y, Djedjos CS, Subramanian GM, Myers RP, Gunn N, Sheikh A, Anstee QM, Romero-Gomez M, Trauner M, Goodman Z, Lawitz EJ, Younossi Z. Selonsertib for Patients with Bridging Fibrosis or Compensated Cirrhosis due to NASH: Results from the STELLAR Phase 3 Trials. Journal of Hepatology 2020, 73(1), 26-39.
  • Liu F, Boon-BeeGoh G, Tiniakos D, Wee A, Leow W, Zhao JM, Rao HY, Wang X, Wang Q, Wan WK, Lim KH, Romero-Gomez M, Petta S, Bugianesi E, Tan CK, Harrison SA, Anstee QM, Chang PJ, Wei L. qFIBS: A Novel Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients with Non-Alcoholic Steatohepatitis. Hepatology 2020, 71(6), 1953-1966.
  • Younes R, Govaere O, Petta S, Miele L, Tiniakos D, Burt A, David E, Vecchio FM, Maggioni M, Cabibi D, Fracanzani AL, Rosso C, GarciaBlanco MJ, Armandi A, Caviglia GP, Zaki MYW, Liguori A, Francione P, Pennisi G, Grieco A, Valenti L, Anstee QM, Bugianesi E. Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease. American Journal of Gastroenterology 2020, 115(8), 1289-1292.
  • Younes R, Govaere O, Petta S, Miele L, Tiniakos D, Burt A, David E, Vecchio FM, Maggioni M, Cabibi D, Fracanzani AL, Rosso C, Blanco MJG, Armandi A, Caviglia GP, Zaki MYW, Liguori A, Francione P, Pennisi G, Grieco A, Valenti L, Anstee QM, Bugianesi E. Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease. American Journal of Gastroenterology 2020, 115(8), 1289-1292.
  • Jarvis H, Craig D, Barker R, Spiers G, Stow D, Anstee QM, Hanratty B. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population based observational studies. PLoS Medicine 2020, 17(4), e1003100.
  • Schneider CV, Hamesch K, Gross A, Mandorfer M, Moeller LS, Pereira V, Pons M, Kuca P, Reichert MC, Benini F, Burbaum B, Voss J, Gutberlet M, Woditsch V, Lindhauer C, Fromme M, Kumpers J, Bewersdorf L, Schaefer B, Eslam M, Bals R, Janciauskiene S, Carvao J, Neureiter D, Zhou B, Woran K, Bantel H, Geier A, Dirrichs T, Stickel F, Teumer A, Verbeek J, Nevens F, Govaere O, Krawczyk M, Roskams T, Haybaeck J, Lurje G, Chorostowska-Wynimko J, Genesca J, Reiberger T, Lammert F, Krag A, George J, Anstee QM, Trauner M, Datz C, Gaisa NT, Denk H, Trautwein C, Aigner E, Strnad P. Liver Phenotypes of European Adults Heterozygous or Homozygous for Pi∗Z Variant of AAT (Pi∗MZ vs Pi∗ZZ genotype) and Noncarriers. Gastroenterology 2020, 159(2), 534-548.e11.
  • McSweeney L, Breckons M, Fattakhova G, Oluboyede Y, Vale L, Ternent L, Balp MM, Doward L, Brass CA, Beyer F, Sanyal A, Anstee QM. Health-Related Quality of Life and Patient-Reported Outcome Measures in NASH-related Cirrhosis. JHEP Reports 2020, 2(3), 100099.
  • Anstee QM, Darlay R, Cockell S, Meroni M, Govaere O, Tiniakos D, Burt AD, Bedossa P, Palmer J, Liu YL, Aithal GP, Allison M, Yki-Järvinen H, Vacca M, Dufour JF, Invernizzi P, Prati D, Ekstedt M, Kechagias S, Francque S, Petta S, Bugianesi E, Clement K, Ratziu V, Schattenberg JM, Valenti L, Day CP, Cordell HJ, Daly AK. Genome-Wide Association Study of Non-Alcoholic Fatty Liver and Steatohepatitis in a Histologically-Characterised Cohort. Journal of Hepatology 2020, 73(3), 505-515.
  • Newsome PN, Sasso M, Deeks JJ, Paredes A, Boursier J, Chan WK, Yilmaz Y, Czernichow S, Zheng MH, Wong VWS, Allison M, Tsochatzis E, Anstee QM, Sheridan DA, Eddowes PJ, Guha IN, Cobbold JF, Paradis V, Bedossa P, Miette V, Fournier-Poizat C, Sandrin L, Harrison SA. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterology and Hepatology 2020, 5(4), 362-373.
  • Scragg J, Avery L, Cassidy S, Taylor G, Haigh L, Boyle M, Trenell MI, Anstee QM, McPherson S, Hallsworth K. Feasibility of a very low calorie diet to achieve a sustainable 10% weight loss in patients with non-alcoholic fatty liver disease. Clinical and Translational Gastroenterology 2020, 11(9), e00231.
  • Younossi ZM, Wong VWS, Anstee QM, Romero-Gomez M, Trauner MH, Harrison SA, Lawitz EJ, Okanoue T, Camargo M, Kersey K, Myers RP, Goodman Z, Stepanova M. Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: The Impact on Patient-Reported Outcomes. Hepatology Communications 2020, 4(11), 1637-1650.
  • Vali Y, Lee J, Boursier J, Spijker R, Löffler J, Verheij J, Brosnan MJ, Böcskei Z, Anstee QM, Bossuyt PM, Zafarmand MH. Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis. Journal of Hepatology 2020, 73(2), 252-262.
  • Anstee QM, Neuschwander-Tetri BA, Wong VW-S, Abdelmalek MF, Younossi ZM, Yuan J, Pecoraro ML, Seyedkazemi S, Fischer L, Bedossa P, Goodman Z, Alkhouri N, Tacke F, Sanyal A. Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design. Contemporary Clinical Trials 2020, 89, 105922.
  • Vacca M, Leslie J, Virtue S, Lam BYH, Govaere O, Tiniakos D, Snow S, Davies S, Petkevicius K, Tong Z, Peirce V, Nielsen MJ, Ament Z, Li W, Kostrzewski T, Leeming DJ, Ratziu V, Allison MED, Anstee QM, Griffin JL, Oakley F, Vidal-Puig A. Bone Morphogenic Protein 8B Promotes the Progression of Non-Alcoholic Steatohepatitis. Nature Metabolism 2020, 2, 514-531.
  • Taylor RS, Taylor RJ, Bayliss S, Hagstrom H, Nasr P, Schattenberg JM, Ishigami M, Toyoda H, Wong VWS, Peleg N, Shlomai A, Sebastiani G, Seko Y, Bhala N, Younossi ZM, Anstee QM, McPherson S, Newsome PN. Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis. Gastroenterology 2020, 158, 1611-1625.
  • Lee J, Vali Y, Boursier J, Duffin K, Verheij J, Brosnan MJ, Zwinderman K, Anstee QM, Bossuyt PM, Zafarmand MH. Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: a systematic review and meta-analysis. PLoS ONE 2020, 15(9), e0238717.
  • Pedrosa M, Seyedkazemi S, Francque S, Sanyal A, Rinella M, Charlton M, Loomba R, Ratziu V, Kochuparampil J, Fischer L, Vaidyanathan S, Anstee QM. A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial. Contemporary Clinical Trials 2020, 88, 105889.
  • Lazarus JV, Ekstedt M, Marchesini G, Mullen J, Novak K, Pericàs JM, Roel E, Romero-Gómez M, Ratziu V, Tacke F, Cortez-Pinto H, Anstee QM. A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe. Journal of Hepatology 2020, 72(1), 14-24.
  • Harrison SA, Ratziu V, Boursier J, Francque S, Bedossa P, Majd Z, Cordonnier G, Sudrik FB, Darteil R, Liebe R, Magnanensi J, Hajji Y, Brozek J, Roudot A, Staels B, Hum DW, Megnien SJ, Hosmane S, Dam N, Chaumat P, Hanf R, Anstee QM, Sanyal AJ. A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study. The Lancet Gastroenterology & Hepatology 2020, 5(11), 970-985.
  • Hallsworth K, Dombrowski SU, McPherson S, Anstee QM, Avery L. Using the theoretical domains framework to identify barriers and enabling factors to implementation of guidance for the diagnosis and management of nonalcoholic fatty liver disease: a qualitative study. Translational Behavioural Medicine 2019, (ePub ahead of Print).
  • Houghton D, Zalewski P, Hallsworth K, Cassidy S, Thoma C, Avery L, Slomko J, Hardy T, Burt AD, Tiniakos D, Hollingsworth KG, Taylor R, Day CP, Masson S, McPherson S, Anstee QM, Newton JL, Trenell MI. The degree of hepatic steatosis associates with impaired cardiac and autonomic function. Journal of Hepatology 2019, 70(6), 1203-1213.
  • Ratziu V, Sanyal AJ, Loomba R, Rinella M, Harrison S, Anstee QM, Goodman Z, Bedossa P, MacConell L, Shringarpure R, Shah A, Younossi Z. REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis. Contemporary Clinical Trials 2019, 84, 105803.
  • Boyle M, Tiniakos D, Schattenberg JM, Ratziu V, Bugianessi E, Petta S, Oliveira CP, Govaere O, Younes R, McPherson S, Bedossa P, Nielsen MJ, Karsdal M, Leeming D, Kendrick S, Anstee QM. Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease. JHEP Reports 2019, 1(3), 188-198.
  • Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, Bedossa P, Geier A, Beckebaum S, Newsome PN, Sheridan D, Sheikh MY, Trotter J, Knapple W, Lawitz E, Abdelmalek MF, Kowdley KV, Montaono-Loza AJ, Boursier J, Mathurin P, Bugianesi E, Mazzella G, Oliveira A, Cortez-Pinto H, Graupera I, Orr D, Gluud LL, Dufour JF, Shapiro D, Campagna J, Zaru L, MacConell L, Shringarpure R, Harrison S, Sanyal AJ. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. The Lancet 2019, 394(10215), 2184-2196.
  • Anstee QM, Lawitz EJ, Alkhouri N, Wong VW, Romero-Gomez M, Okanoue T, Trauner M, Kersey K, Li G, Han L, Jia C, Wang L, Chen G, Subramanian GM, Myers RP, Djedjos CS, Kohli A, Bzowej N, Younes Z, Sarin S, Shiffman ML, Harrison SA, Afdhal NH, Goodman Z, Younossi ZM. Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials. Hepatology 2019, 70(5), 1521-1530.
  • Huber Y, Boyle M, Hallsworth K, Tiniakos D, Straub BK, Labenz C, Ruckes C, Galle PR, Romero-Gómez M, Anstee QM, Schattenberg JM. Health-related Quality of Life in Non-alcoholic Fatty Liver Disease Associates With Hepatic Inflammation. Clinical Gastroenterology and Hepatology 2019, 17(10), 2085-2092.e1.
  • Dewar A, Anstee QM, Price DA, Payne BAI. Central obesity and non-alcoholic fatty liver disease in people living with HIV: a case for targeted screening?. HIV Medicine 2019, 20(1), e1-e2.
  • Haigh L, Bremner S, Houghton D, Henderson E, Avery L, Hardy T, Hallsworth K, McPherson S, Anstee QM. Barriers and Facilitators to Mediterranean Diet Adoption by Patients with Non-alcoholic Fatty Liver Disease in Northern Europe. Clinical Gastroenterology and Hepatology 2019, 17(7), 1364-1371.e3.
  • Eddowes PJ, Sasso M, Allison M, Tsochatzis E, Anstee QM, Sheridan D, Guha IN, Cobbold JF, Deeks JJ, Paradis V, Bedossa P, Newsome PN. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Non-alcoholic Fatty Liver Disease. Gastroenterology 2019, 156(6), 1717-1730.
  • Dhar A, Sadiq F, Anstee QM, Levene AP, Goldin RD, Thursz MR. Thrombin and factor Xa link the coagulation system with liver fibrosis. BMC Gastroenterology 2018, 18, 60.
  • Krenkel O, Puengel T, Govaere O, Abdallah AT, Mossanen JC, Kohlhepp M, Liepelt A, Lefebvre E, Luedde T, Hellerbrand C, Weiskirchen R, Longerich T, Costa IG, Anstee QM, Trautwein C, Tacke F. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis. Hepatology 2018, 67(4), 1270-1283.
  • Boyle M, Masson S, Anstee QM. The bidirectional impacts of alcohol consumption and the metabolic syndrome: Cofactors for progressive fatty liver disease. Journal of Hepatology 2018, 68(2), 251-267.
  • Anstee QM, Mantovani A, Tilg H, Targher G. Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease. Nature Reviews Gastroenterology and Hepatology 2018, 15, 425-439.
  • Cobbold JF, Atkinson S, Marchesi JR, Smith A, Wai SN, Stove J, Shojaee-Moradie F, Jackson N, Umpleby AM, Fitzpatrick J, Thomas EL, Bell JD, Holmes E, Taylor-Robinson SD, Goldin RD, Yee MS, Anstee QM, Thursz MR. Rifaximin in non-alcoholic steatohepatitis: An open-label pilot study. Hepatology Research 2018, 48(1), 69-77.
  • Labenz C, Huber Y, Kalliga E, Nagel M, Ruckes C, Straub BK, Galle PR, Worns M-A, Anstee QM, Schuppan D, Schattenberg JM. Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany. Alimentary Pharmacology and Therapeutics 2018, 48(10), 1109-1116.
  • Petta S, Sebastiani G, Bugianesi E, Viganò M, Wong VWS, Berzigotti A, Fracanzani AL, Anstee QM, Marra F, Barbara M, Calvaruso V, Cammà C, Di Marco V, Craxì A, de Ledinghen V. Noninvasive Prediction of Esophageal Varices by Stiffness and Platelet in Nonalcoholic Fatty Liver Disease Cirrhosis. Journal of Hepatology 2018, 69(4), 878-885.
  • Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, Colombo M, Craxi A, Crespo J, Day CP, Geier A, Kondili LA, Lazarus JV, Loomba R, Manns MP, Marchesini G, Negro F, Petta S, Ratziu V, Romero-Gomez M, Sanyal A, Schattenberg JM, Tacke F, Trautwein C, Wei L, Zeuzem S, Razavi H. Modeling NAFLD Disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. Journal of Hepatology 2018, 69(4), 896-904.
  • Mann JP, Vreugdenhil A, Socha P, Janczyk W, Baumann U, Rajwal S, Casswall T, Marcus C, van Mourik I, O'Rahilly S, Savage DB, Noble-Jamieson G, Lacaille F, Dabbas M, Dubern B, Kelly DA, Nobili V, Anstee QM. European paediatric non-alcoholic fatty liver disease registry (EU-PNAFLD): Design and rationale. Contemporary Clinical Trials 2018, 75, 67-71.
  • Siddiqui MS, Harrison SA, Abdelmalek MF, Anstee QM, Bedossa P, Castera L, Dimick-Santos L, Friedman SL, Greene K, Kleiner DE, Megnien S, Neuschwander-Tetri BA, Ratziu V, Schabel E, Miller V, Sanyal AJ. Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science. Hepatology 2018, 67(5), 2001-2012.
  • Codner GF, Mianne J, Caulder A, Loeffler J, Fell R, King R, Allan AJ, Mackenzie M, Pike FJ, McCabe CV, Christou S, Joynson S, Hutchison M, Stewart ME, Kumar S, Simon MM, Agius L, Anstee QM, Volynski KE, Kullmann DM, Wells S, Teboul L. Application of long single-stranded DNA donors in genome editing: Generation and validation of mouse mutants. BMC Biology 2018, 16(1), 70.
  • Codner GF, Mianné J, Caulder A, Loeffler J, Fell R, King R, Allan AJ, Mackenzie M, Pike FJ, McCabe CV, Christou S, Joynson S, Hutchison M, Stewart ME, Kumar S, Simon MM, Agius L, Anstee QM, Volynski KE, Kullmann DM, Wells S, Teboul L. Application of long single-stranded DNA donors in genome editing: generation and validation of mouse mutants. BioMedCentral Biology 2018, 16, 70.
  • Isokuortti E, Zhou Y, Peltonen M, Bugianesi E, Clement K, Bonnefont-Rousselot D, Lacorte J-M, Gastaldelli A, Schuppan D, Schattenberg JM, Hakkarainen A, Lundbom N, Jousilahti P, Mannisto S, Keinanen-Kiukaanniemi S, Saltevo J, Anstee QM, Yki-Jarvinen H. Use of HOMA-IR to diagnose non-alcoholic fatty liver disease: a population-based and inter-laboratory study. Diabetologia 2017, 60(10), 1873-1882.
  • Liu W, Anstee QM, Wang X, Gawrieh S, Gamazon ER, Athinarayanan S, Liu Y-L, Darlay R, Cordell HJ, Daly AK, Day CP, Chalasani N. Transcriptional regulation of PNPLA3 and its impact on susceptibility to nonalcoholic fatty liver Disease (NAFLD) in humans. Aging 2017, 9(1), 26-40.
  • Govaere O, Petz M, Wouters J, Vandewynckel Y-P, Scott EJ, Topal B, Nevens F, Verslype C, Anstee QM, Van Vlierberghe H, Mikulits W, Roskams T. The PDGFRα-laminin B1-keratin 19 cascade drives tumor progression at the invasive front of human hepatocellular carcinoma. Oncogene 2017, 36, 6605-6616.
  • Donati B, Pietrelli A, Pingitore P, Dongiovanni P, Caddeo A, Walker L, Baselli G, Pelusi S, Rosso C, Vanni E, Daly A, Mancina RM, Grieco A, Miele L, Grimaudo S, Craxi A, Petta S, De Luca L, Maier S, Soardo G, Bugianesi E, Colli F, Romagnoli R, Anstee QM, Reeves HL, Fracanzani AL, Fargion S, Romeo S, Valenti L. Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. Cancer Medicine 2017, 6(8), 1930-1940.
  • Hardy T, Zeybel M, Day CP, Dipper C, Masson S, McPherson S, Henderson E, Tiniakos D, White S, French J, Mann DA, Anstee QM, Mann J. Plasma DNA methylation: A potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease. Gut 2017, 66(7), 1321-1328.
  • Adams LA, Anstee QM, Tilg H, Targher G. Non-Alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 2017, 66(6), 1138-1153.
  • Mann JP, Anstee QM. NAFLD: PNPLA3 and obesity: a synergistic relationship in NAFLD. Nature Reviews Gastroenterology and Hepatology 2017, 14(9), 506-507.
  • Donati B, Dongiovanni P, Romeo S, Meroni M, McCain M, Miele L, Petta S, Maier S, Rosso C, De Luca L, Vanni E, Grimaudo S, Romagnoli R, Colli F, Ferri F, Mancina R, Iruzubieta P, Craxi A, Fracanzani A, Grieco A, Corradini S, Aghemo A, Colombo M, Soardo G, Bugianesi E, Reeves H, Anstee Q, Fargion S, Valenti L. MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals. Scientific Reports 2017, 7, 4492.
  • Avery L, Exley C, McPherson S, Trenell MI, Anstee QM, Hallsworth K. Lifestyle Behavior Change in Patients With Nonalcoholic Fatty Liver Disease: A Qualitative Study of Clinical Practice. Clinical Gastroenterology and Hepatology 2017, 15(12), 1968-1971.
  • Shalapour S, Lin XJ, Bastian IN, Brain J, Burt AD, Aksenov AA, Vrbanac AF, Li W, Perkins A, Matsutani T, Zhong Z, Dhar D, Navas-Molina JA, Xu J, Loomba R, Downes M, Yu RT, Evans RM, Dorrestein PC, Knight R, Benner C, Anstee QM, Karin M. Inflammation-induced IgA⁺ cells dismantle anti-liver cancer immunity. Nature 2017, 551(7680), 340-345.
  • Luukkonen PK, Zhou Y, Nidhina Haridas PA, Dwivedi OP, Hyotylainen T, Ali A, Juuti A, Leivonen M, Tukiainen T, Ahonen L, Scott E, Palmer JM, Arola J, Orho-Melander M, Vikman P, Anstee QM, Olkkonen VM, Oresic M, Groop L, Yki-Jarvinen H. Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLD. Journal of Hepatology 2017, 67(1), 128-136.
  • McCabe WA, Way MJ, Ruparelia K, Knapp S, Ali MA, Anstee QM, Thomas HC, McQuillin A, Morgan MY. Genetic variation in GABRβ1 and the risk for developing alcohol dependence. Psychiatric Genetics 2017, 27(3), 110-115.
  • Houghton D, Thoma C, Hallsworth K, Cassidy S, Hardy T, Burt AD, Tiniakos D, Hollingsworth KG, Taylor R, Day CP, McPherson S, Anstee QM, Trenell MI. Exercise Reduces Liver Lipids and Visceral Adiposity in Patients With Nonalcoholic Steatohepatitis in a Randomized Controlled Trial. Clinical Gastroenterology and Hepatology 2017, 15(1), 96-102.e3.
  • Houghton D, Hallsworth K, Thoma C, Cassidy S, Hardy T, Heaps S, Hollingsworth KG, Taylor R, Day CP, Masson S, McPherson S, Anstee QM, Trenell MI. Effects of Exercise on Liver Fat and Metabolism in Alcohol Drinkers. Clinical Gastroenterology and Hepatology 2017, 15(10), 1596-1603.e3.
  • Ogrodnik M, Miwa S, Tchkonia T, Tiniakos D, Wilson CL, Lahat A, Day CP, Burt A, Palmer A, Anstee QM, Nagaraja Grellscheid S, Hoeijmakers JHJ, Barnhoorn S, Mann DA, Bird TG, Vermeij WP, Kirkland JL, Passos JF, von Zglinicki T, Jurk D. Cellular senescence drives age-dependent hepatic steatosis. Nature Communications 2017, 8, 15691.
  • Sheridan DA, Aithal G, Alazawi W, Allison M, Anstee Q, Cobbold J, Khan S, Fowell A, McPherson S, Newsome PN, Oben J, Tomlinson J, Tsochatzis E. Care standards for non-alcoholic fatty liver disease in the United Kingdom 2016: a cross-sectional survey. Frontline Gastroenterology 2017, 8(4), 252-259.
  • McPherson S, Hardy T, Dufour JF, Petta S, Romero-Gomez M, Allison M, Oliveira CP, Francque S, Van Gaal L, Schattenberg JM, Tiniakos D, Burt AD, Bugianesi E, Ratziu V, Day CP, Anstee QM. Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis. American Journal of Gastroenterology 2017, 112(5), 740-751.
  • McPherson S, Wilkinson N, Tiniakos D, Wilkinson J, Burt AD, McColl E, Stocken DD, Steen N, Barnes J, Goudie N, Stewart S, Bury Y, Mann D, Anstee QM, Day CP. A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis. PLoS One 2017, 12(4), e0175717.
  • Anstee QM, Seth D, Day CP. Genetic Factors That Affect Risk of Alcoholic and Nonalcoholic Fatty Liver Disease. Gastroenterology 2016, 150(8), 1728-1744.e7.
  • Ratziu V, Harrison SA, Francque S, Bedossa P, Lehert P, Serfaty L, Romero-Gomez M, Boursier J, Abdelmalek M, Caldwell S, Drenth J, Anstee QM, Hum D, Hanf R, Roudot A, Megnien S, Staels B, Sanyal A, GOLDEN-505 Investigator Study Group. Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. Gastroenterology 2016, 150(5), 1147-1159.
  • Munteanu M, Tiniakos D, Anstee Q, Charlotte F, Marchesini G, Bugianesi E, Trauner M, Romero Gomez M, Oliveira C, Day C, Dufour JF, Bellentani S, Ngo Y, Traussnig S, Perazzo H, Deckmyn O, Bedossa P, Ratziu V, Poynard T, FLIP Consortium and the FibroFrance Group Collaborators, Ratziu V, Poynard T, Castille JM, Ngo Y, Langon T, Lawlor D, Marchesini G, Marra F, Bugianesi E, Bellentani S, Dufour JF, Romero Gomez M, Sørensen T, Tribelli C, DeMinicis S, Trauner M, Oliveira C, Bedossa P, Burt AD, Gouw AS, Lackner C, Schirmacher P, Terracciano L, Tiniakos D, Brain J, Bury Y, Cabibi D, Charlotte F, David E, Losi L, Montani M, Pareja MJ, Wendum D, Wrba F, Ziol M, Poynard T, Thabut D, Moussalli J, Lebray P, Rudler M, Bismuth FI, Charlotte F, Rosmorduc O, Calmus Y, Hartemann A, Jacqueminet S, Bruckert E, Giral P, Naveau S, Perlemuter G, Varsat B, Mercadier A. Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference. Alimentary Pharmacology and Therapeutics 2016, 44(8), 877-889.
  • Weston CJ, Shepherd EL, Claridge LC, Rantakari P, Curbishley SM, Tomlinson JW, Hubscher SG, Reynolds GM, Aalto K, Anstee QM, Jalkanen S, Salmi M, Smith DJ, Day CP, Adams DH. Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosis. Journal of Clinical Investigation 2015, 125(2), 501-520.
  • Possamai LA, McPhail MJW, Khamri W, Wu BS, Concas D, Harrison M, Williams R, Cox RD, Cox IJ, Anstee QM, Thursz MR. The role of intestinal microbiota in murine models of acetaminophen-induced hepatotoxicity. Liver International 2015, 35(3), 764-773.
  • Hardy T, Anstee QM, Day CP. Nonalcoholic fatty liver disease: new treatments. Current Opinion in Gastroenterology 2015, 31(3), 175-183.
  • Hallsworth K, Thoma C, Hollingsworth KG, Cassidy S, Anstee QM, Day CP, Trenell MI. Modified high-intensity interval training reduces liver fat and improves cardiac function in non-alcoholic fatty liver disease: A randomised controlled trial. Clinical Science 2015, 129(12), 1097-1105.
  • McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management. Journal of Hepatology 2015, 62(5), 1148-1155.
  • Zeybel M, Hardy T, Robinson SM, Fox C, Anstee QM, Ness T, Masson S, Mathers JC, French J, White S, Mann J. Differential DNA methylation of genes involved in fibrosis progression in non-alcoholic fatty liver disease and alcoholic liver disease. Clinical Epigenetics 2015, 7(25).
  • Liu Y-L, Reeves HL, Burt AD, Tiniakos D, McPherson S, Leathart JBS, Allison MED, Alexander GJ, Piguet A-C, Anty R, Donaldson P, Aithal GP, Francque S, VanGaal L, Clement K, Ratziu V, Dufour J-F, Day CP, Daly AK, Anstee QM. TM6SF2 rs58542926 Influences Hepatic Fibrosis Progression in Patients with Non-Alcoholic Fatty Liver Disease. Nature Communications 2014, 5, 4309.
  • McPherson S, Henderson E, Burt AD, Day CP, Anstee QM. Serum immunoglobulin levels predict fibrosis in patients with non-alcoholic fatty liver disease. Journal of Hepatology 2014, 60(5), 1055-1062.
  • Hallsworth K, Thoma C, Moore S, Ploetz T, Anstee QM, Taylor R, Day CP, Trenell MI. Non-alcoholic fatty liver disease is associated with higher levels of objectively measured sedentary behaviour and lower levels of physical activity than matched healthy controls. Frontline Gastroenterology 2014, 1-8.
  • Anty R, Tonohouan M, Ferrari-Panaia P, Piche T, Pariente A, Anstee QM, Gual P, Tran A. Low Levels of 25-Hydroxy Vitamin D are Independently Associated with the Risk of Bacterial Infection in Cirrhotic Patients. Clinical and Translational Gastroenterology 2014, 5, 1-10.
  • Aravinthan A, Mells G, Allison M, Leathart J, Kotronen A, Yki-Jarvinen H, Daly AK, Day CP, Anstee QM, Alexander G. Gene Polymorphisms of Cellular Senescence Marker P21 and Disease Progression in Non-Alcohol-Related Fatty Liver Disease. Cell Cycle 2014, 13(9), 1489-1494.
  • Liu Y-L, Patman GL, Leathart J, Piguet A-C, Burt AD, Dufour J-F, Day CP, Daly AK, Reeves HL, Anstee QM. Carriage of the PNPLA3 rs738409 C>G Polymorphism Confers an Increased Risk of Non-Alcoholic Fatty Liver Disease Associated Hepatocellular Carcinoma. Journal of Hepatology 2014, 61(1), 75-81.
  • Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nature Reviews Gastroenterology and Hepatology 2013, 10(6), 330-344.
  • Anstee QM, Knapp S, Maguire EP, Hosie AM, Thomas P, Mortensen M, Bhome R, Martinez A, Walker SE, Dixon CI, Ruparelia K, Montagnese S, Kuo YT, Herlihy A, Bell JD, Robinson I, Guerrini I, McQuillin A, Fisher EMC, Ungless MA, Gurling HMD, Morgan MY, Brown SDM, Stephens DN, Belelli D, Lambert J, Smart T, Thomas HC. Mutations in the Gabrb1 gene promote alcohol consumption through increased tonic inhibition. Nature Communications 2013, 4, 1-11.
  • Goldsworthy M, Absalom NL, Schröter D, Matthews HC, Bogani D, Moir L, Long A, Church C, Hugill A, Anstee QM, Goldin R, Thursz M, Hollfelder F, Cox RD. Mutations in Mll2, an H3K4 methyltransferase, result in insulin resistance and impaired glucose tolerance in mice. PLOS One 2013, 8(6), e61870.
  • Hallsworth K, Hollingsworth KG, Thoma C, Jakovljevic DG, MacGowan GA, Anstee QM, Taylor R, Day CP, Trenell MI. Cardiac structure and function are altered in adults with non-alcoholic fatty liver disease. Journal of Hepatology 2013, 58(4), 757-762.
  • McPherson S, Anstee QM, Henderson E, Day CP, Burt AD. Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels?. European Journal of Gastroenterology & Hepatology 2013, 25(6), 652-658.
  • Al-Serri A, Anstee QM, Valenti L, Nobili V, Leathart JBS, Dongiovanni P, Patch J, Fracanzani A, Fargion S, Day CP, Daly AK. The SOD2 C₄₇T polymorphism influences NAFLD fibrosis severity: Evidence from case-control and intra-familial allele association studies. Journal of Hepatology 2012, 56(2), 448-454.
  • Levene AP, Kudo H, Armstrong MJ, Thursz MR, Gedroyc WM, Anstee QM, Goldin RD. Quantifying hepatic steatosis - more than meets the eye. Histopathology 2012, 60(6), 971-981.
  • Zeybel M, Hardy T, Wong YK, Mathers JC, Fox CR, Gackowska A, Oakley F, Burt AD, Wilson CL, Anstee QM, Barter MJ, Masson S, Elsharkawy AM, Mann DA, Mann J. Multigenerational epigenetic adaptation of the hepatic wound-healing response. Nature Medicine 2012, 18(9), 1369-U110.
  • Anstee QM, Day CP. A lipid to treat non-alcoholic fatty liver disease – The dawn of ‘lipo-rehabilitation’?. Journal of Hepatology 2012, 56(4), 987-989.
  • Anstee QM, Dhar A, Thursz MR. The role of hypercoagulability in liver fibrogenesis. Clinics and Research in Hepatology and Gastroenterology 2011, 35(8-9), 526-533.
  • Sauvage VR, Levene AP, Nguyen HT, Wood TC, Kudo H, Concas D, Thomas HC, Thursz MR, Goldin RD, Anstee QM, Elson DS. Multi-Excitation Fluorescence Spectroscopy for Analysis of Non-Alcoholic Fatty Liver Disease. Lasers in Surgery and Medicine 2011, 43(5), 392-400.
  • Anstee QM, McPherson S, Day CP. How big a problem is non-alcoholic fatty liver disease?. BMJ 2011, 343, d3897.
  • Possamai LA, Antoniades CG, Anstee QM, Quaglia A, Vergani D, Thursz MR, Wendon J. Role of monocytes and macrophages in experimental and human acute liver failure. World Journal of Gastroenterology 2010, 16(15), 1811-1819.
  • Cobbold JFL, Anstee QM, Thomas HC. Rational Testing: Investigating mildly abnormal serum aminotransferase values. British Medical Journal 2010, 341, c4039.
  • Anstee QM, Concas D, Kudo H, Levene A, Pollard J, Charlton P, Thomas HC, Thursz MR, Goldin RD. Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis. Journal of Hepatology 2010, 53(3), 542-550.
  • Cobbold JFL, Anstee QM, Goldin RD, Williams HRT, Matthews HC, North BV, Absalom N, Thomas HC, Thursz MR, Cox RD, Taylor-Robinson SD, Cox IJ. Phenotyping murine models of non-alcoholic fatty liver disease through metabolic profiling of intact liver tissue. Clinical Science 2009, 116(5-6), 403-413.
  • Anstee QM, Wright M, Goldin R, Thursz MR. Parenchymal extinction: coagulation and hepatic fibrogenesis. Clinics in Liver Disease 2009, 13(1), 117-126.
  • Kelly ML, Moir L, Jones L, Whitehill E, Anstee QM, Goldin RD, Hough A, Cheeseman M, Jansson JO, Peters J, Cox RD. A missense mutation in the non-neural G-protein α-subunit isoforms modulates susceptibility to obesity. International Journal of Obesity 2009, 33(5), 507-518.
  • Northup PG, Sundaram V, Fallon MB, Reddy KR, Balogun RA, Sanyal AJ, Anstee QM, Hoffman MR, Ikura Y, Caldwell H, The Coagulation in Liver Disease Group. Hypercoagulation and thrombophilia in liver disease. Journal of Thrombosis and Haemostasis 2008, 6(1), 2-9.
  • Martinelli A, Knapp S, Anstee QM, Worku M, Tommasi A, Zucoloto S, Goldin R, Thursz M. Effect of a thrombin receptor (protease-activated receptor 1, PAR-1) gene polymorphism in chronic hepatitis C liver fibrosis. Journal of Gastroenterology and Hepatology 2008, 23(9), 1403-1409.
  • Anstee QM, Goldin RD, Wright M, Martinelli A, Cox R, Thursz MR. Coagulation status modulates murine hepatic fibrogenesis: implications for the development of novel therapies. Journal of Thrombosis and Haemostasis 2008, 6(8), 1336-1343.
  • Anstee QM, Goldin RD. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. International Journal of Experimental Pathology 2006, 87(1), 1-16.
  • Anstee QM, Forbes A. The safe use of percutaneous gastrostomy for enteral nutrition in patients with Crohn's disease. European Journal of Gastroenterology & Hepatology 2000, 12(10), 1089-1093.
  • Lopes LM, Hughson E, Anstee QM, O'Neil D, Katz DR, Chain BM. Vectorial function of major histocompatibility complex class II in a human intestinal cell line. Immunology 1999, 98(1), 16-26.
  • Anstee QM, Forbes A. [Abstract] Safety of percutaneous gastrostomy (PEG) feeding in Crohn's disease. Gastroenterology 1999, 116(4 (part 2)), A662 abstract no. G2889.
  • Anstee QM, Forbes A. [Abstract] Safety of percutaneous gastrostomy (PEG) feeding in Crohn's disease. Gut 1999, 44(supplement 1), A36 abstract no. T144.

• Book Chapters

  • Bellamy C, Burt AD. The Liver in Systemic Disease. In: Burt, AD; Ferrell, LD; Hubscher, SG, ed. MacSween's Pathology of the Liver (Seventh Edition). Elsevier Inc, 2018, pp.966-1018.
  • Tiniakos DG, Anstee QM, Burt AD. Fatty Liver Disease. In: Burt, AD; Ferrell, LD; Hubscher, SG, ed. MacSween's Pathology of the Liver. Elsevier Inc, 2018, pp.308-371.
  • Anstee QM, Jones D. Liver and Biliary Tract Disease. In: Walker BR, Colledge NR, Ralston AH & Penman ID, ed. Davidson's Principles & Practice of Medicine. Churchill Livingstone, 2014.
  • Anstee QM, Smith BC, Thomas HC. Hepatitis B and hepatitis C co-infection. In: Foster, G.R., Rajender Reddy, K, ed. Clinical Dilemmas in Viral Liver Disease. Oxford: Wiley-Blackwell, 2010, pp.192-198.

• Conference Proceedings (inc. Abstracts)

  • Jarvis H, O'Keefe H, Craig D, Stow D, Anstee Q, Hanratty B. People with NAFLD also drink alcohol - how should we advise and manage this expanding group in primary care? A systematic review. In: Society for Academic Primary Care (SAPC) Annual Scientific Meeting 2020. 2020, University of Leeds: Society for Academic Primary Care (SAPC).
  • Breckons M, Doward L, Magdalena Balp M, Twiss J, Oluboyede Y, Vale L, Ternent L, Brass C, Sanyal A, Anstee Q. Evaluating the patient-perceived impact of non-alcoholic steatohepatitis with compensated cirrhosis. In: The Digital International Liver Congress. 2020, Online: EASL.
  • Houghton D, Zalewski P, Cassidy S, Thoma C, Hallsworth K, Avery L, Lukowska AB, Hardy T, Burt AD, Masson S, Day C, McPherson S, Anstee QM, Newton JL, Trenell MI. Autonomic function is impaired across the spectrum of NAFLD. In: The International Liver Congress 2017: 52nd Annual Meeting of the European Association for the Study of the Liver. 2017, Amsterdam, The Netherlands: Elsevier BV.
  • Francque SM, Ratziu V, Harrison S, Anstee QM, Bedossa P, Cordonnier G, Brozek J, Ben Sudrik F, Hum DW, Megnien S, Roudot A, Staels B, Hanf R, Darteil R, Sanyal AJ. Validation of mir-34a, mir-122 and mir-200a as bio-markers for identification of NASH patients eligible for treatment. In: 67th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2016. 2016, Boston, Massachusetts, USA: John Wiley & Sons, Inc.
  • Eddowes PJ, Anstee Q, Guha IN, Sheridan DA, Tsochatzis E, Cobbold J, Allison ME, Paradis V, Bedossa P, Newsome P. Staging fibrosis and excluding advanced fibrosis in patients with NAFLD: comparison of non-invasive markers in an interim analysis from a prospective multicentre study. In: 67th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2016. 2016, Washington DC: Wiley.
  • Eddowes PJ, Anstee Q, Guha IN, Sheridan DA, Tsochatzis E, Cobbold J, Allison ME, de Ledinghen V, Sasso M, Fournier C, Miette V, Paradis V, Bedossa P, Newsome PN. Novel Fibroscan-Based Score to Diagnose NASH and its severity in A Multi-centre UK Cohort of Patients with Suspected NAFLD. In: 67th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2016. 2016, Washington DC: Wiley-Blackwell.
  • Ratziu V, Francque SM, Harrison S, Anstee QM, Bedossa P, Brozek J, Hum DW, Megnien S, Roudot A, Hanf R, Staels B, Sanyal AJ. Improvement in NASH histological activity highly correlates with fibrosis regression. In: 67th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2016. 2016, Boston, Massachusetts, USA: John Wiley & Sons, Inc.
  • de Alwis NMW, Anstee QM, Day CP. How to Diagnose Nonalcoholic Fatty Liver Disease. In: Gut-Liver Interactions: From IBD to NASH. 2016, Innsbruck: S. Karger AG.
  • Houghton DH, Thoma CT, Cassidy SC, Hallsworth KH, Hollingsworth KGH, Taylor RT, Day CPD, Anstee QMA, Trenell MIT. Exercise reduces liver fat and improves body composition but not insulin sensitivity or inflammatory markers in non-alcoholic steatohepatitis. In: Diabetes UK Professional Conference. 2016, Glasgow: Wiley-Blackwell Publishing Ltd.
  • Ratziu V, Harrison SA, Francque S, Bedossa P, Anstee QM, Ben Sudrik F, Roudot A, Megnien S, Hum DW, Hanf R, Staels B, Sanyal AJ. ALT as a non-invasive biomarker of histological response to pharmacotherapy in NASH patients: insights from the elafibranor GOLDEN505 trial. In: 67th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2016. 2016, Washington DC: Wiley-Blackwell.
  • Dhar A, Tschotazis E, Brown R, Manousou P, Millson C, Aldersley M, Forbes S, Aggarwal K, Gera A, Cramp M, Holt A, Mutimer D, McPherson S, Burroughs A, Anstee Q, Goldin R, Thursz MR. Wafarin anticoagulation for liver fibrosis in patients transplanted for hepatitis C (WAFT-C): results at one year. In: 50th Annual Meeting of the European Association for the Study of the Liver. 2015, Vienna, Austria: Elsevier.
  • Anty R, Liu YL, Iannelli A, Patouraux S, Canivet C, Ben-Amor I, Schneck AS, Saint-Paul MC, Gugenheim J, Day C, Daly A, Tran A, Gual P, Anstee Q. The FNDC5 rs3480 is protective on the steatosis and fibrosis in patients with NAFLD. In: 50th Annual Meeting of the European Association for the Study of the Liver. 2015, Vienna, Austria: Elsevier.
  • Donati B, Vanni E, Dongiovanni P, Iavarone M, Rametta R, Rosso C, Carnelutti A, Petta S, Fracanzani AL, Reeves HL, Dofour JF, Miele L, Anstee Q, Bugianesi E, Soardo G, Fargion S, Valenti L. Telomerase reverse transcriptase mutations are associated with hepatocellular carcinoma in nash. In: 50th Annual Meeting of the European Association for the Study of the Liver. 2015, Vienna, Austria: Elsevier.
  • Whitehead A, Ogle L, Patman GL, Anwar G, Tiniakos DG, Anstee QM, Reeves HL, FLIP Investigators FP7 2007-2013 H. Ras and p-ERK in metabolic syndrome associated Hepatocellular Carcinoma (HCC). In: 50th Annual Meeting of the European Association for the Study of the Liver. 2015, Vienna, Austria: Elsevier.
  • Palmer J, Liu YL, Day CP, Daly A, Anstee QM. Mechanistic Study of TM6SF2 in NAFLD pathogenesis: Stably transfected Huh7 cells over-expressing the TM6SF2 E167K variant exhibit greater levels of oxidative stress. In: 50th Annual Meeting of the European Association for the Study of the Liver. 2015, Vienna, Austria: Elsevier.
  • Hardy T, Sharkey V, Zeybel M, Mathers JC, French J, White S, Mann DA, Anstee QM, Mann J. Laser capture microdissection reveals cell-specific DNA methylation signatures in key fibrosis modifier genes in chronic liver disease. In: The International Liver Congress 2015 - 50th Annual meeting of the European Association for the Study of the Liver. 2015, Vienna, Austria: Elsevier BV.
  • McPherson S, Hardy T, Henderson E, Allison M, Ratziu V, Francque S, Burt AD, Day C, Anstee QM. High rate of false positives for advanced fibrosis when simple non-invasive fibrosis tests are used in older patients (>=65 years) with NAFLD. In: 2nd Digestive Disorders Federation Conference. 2015, London, UK: BMJ Group.
  • Houghton D, Thoma C, Hallsworth K, Hollingsworth KG, Day CP, Anstee QM, Trenell MI. Exercise reduces liver fat, visceral fat and circulating triglycerides, but not circulating inflammatory markers in non-alcoholic steatohepatitis. In: The International Liver Congress 2015 - 50th Annual meeting of the European Association for the Study of the Liver. 2015, Vienna, Austria: Elsevier BV.
  • Whitehead A, Patman GL, Deuschle U, Day CP, Kremoser C, Tiniakos DG, Anstee QM, Reeves HL, FLIP Investigators FP7 2007-2013 H. Effects of FXR agonist PX20606 on tumour formation in animal models of non-alcoholic fatty liver disease. In: The International Liver Congress 2015 - 50th Annual meeting of the European Association for the Study of the Liver. 2015, Vienna, Austria: Elsevier.
  • Mcpherson S, Henderson E, Hardy T, Burt A, Day C, Anstee QM. Natural History of NAFLD: A Study of 108 Patients with Paired Liver Biopsies. In: British Society of Gastroenterology Annual General Meeting. 2014, Manchester, UK: BMJ Publishing Group.
  • McPherson S, Henderson E, Hardy T, Burt AD, Day C, Anstee QM. Natural history of NAFLD: A study of 108 patients with paired liver biopsies. In: British Society of Gastroenterology Annual General Meeting. 2014, Manchester, UK: BMJ Group.
  • Zeybel M, Hardy T, Fox C, Masson S, Mann D, Mathers J, Anstee Q, Mann J. Differential DNA methylation of genes involved in fibrosis progression in NAFLD and ALD. In: The International Liver Congress 2014: 49th Annual Meeting of the European Association for the Study of the Liver. 2014, London: Elsevier BV.
  • Cobbold JFL, Wai SN, Stove J, Shojaee-Moradie F, Fitzpatrick J, Thomas EL, Bell JD, Goldin RD, Taylor-Robinson SD, Yee MS, Anstee QM, Thursz MR. Rifaximin in Non-Alcoholic Steatohepatitis: An Open-Label Pilot Study. In: 48th Annual Meeting of the European Association for the Study of the Liver. 2013, Amsterdam, The Netherlands: Elsevier.
  • Patman GL, Televantou D, Whitehead A, Day CP, Oakley F, Mann DA, Burt AD, Anstee QM, Reeves HL, FLIP Investigators FP7-2007-2013. Mild Steatosis and Impaired Glucose Tolerance are Associated with Liver Cancer Development, While Progression to Nash Increases Number/Size in an Animal Model of NAFLD. In: 48th Annual meeting of the European Association for the Study of the Liver. 2013, Amsterdam, Netherlands: Elsevier BV.
  • Wang X, Onjiko RM, Anstee QM, Ratziu V, Liu YL, Cordell HJ, Darlay R, Day CP, Daly AK, Chalasani N, Liu W, FLIP Fatty Liver Inhibition Progression. Mapping Expression Quantitative Traits Loci (EQTL) for PNPLA3 Gene Identifies Additional SNPs Associated with Non-Alcoholic Fatty Liver Disease (NAFLD) Independent of rs738409. In: 48th Annual meeting of the European Association for the Study of the Liver. 2013, Amsterdam, Netherlands: Elsevier BV.
  • Thoma C, Hallsworth K, Hollingsworth K, Anstee Q, Taylor R, Day C, Trenell M. HIGH-INTENSITY INTERMITTENT EXERCISE THERAPY REDUCES LIVER FAT AND IMPROVES BODY COMPOSITION IN ADULTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE. In: 48th Annual Meeting of the European Association for the Study of the Liver. 2013, Amsterdam, The Netherlands: Elsevier BV.
  • Hallsworth K, Thoma C, Moore S, Ploetz T, Anstee QM, Day CP, Trenell MI. Higher Objectively Measured Sedentary Behaviour and Lower Levels of Physical Activity than Matched Healthy Controls. In: 48th Annual meeting of the European Association for the Study of the Liver. 2013, Amsterdam, Netherlands: Elsevier BV.
  • Barrie T, Yeung S, Fathima S, Anstee QM, Masson S, Mcpherson S. Does the Pre-Bone Mineral Density Frax Score Predict Fracture Risk in Patients with Cirrhosis?. In: British Society of Gastroenterology Annual General Meeting. 2013, Glasgow, UK: BMJ Publishing Group.
  • Liu YL, Patman G, Leathart J, Burt A, Day CP, Daly AK, Reeves H, Anstee QM, FLIP Fatty Liver Inhibition Progression. Carriage of PNPLA3 I148M is Associated with an Increased Risk of Non-Alcoholic Fatty Liver Disease Associated Hepatocellular Carcinoma. In: 48th Annual meeting of the European Association for the Study of the Liver. 2013, Amsterdam, Netherlands: Elsevier Science BV.
  • Hallsworth K, Hollingsworth KG, Thoma C, Anstee QM, Day CP, Trenell MI. Cardiac Function Improves Following High Intensity Intermittent Exercise Therapy in Non-Alcoholic Fatty Liver Disease. In: 48th Annual meeting of the European Association for the Study of the Liver. 2013, Amsterdam, Netherlands: Elsevier Science BV.
  • Hallsworth K, Hollingsworth KG, Thoma C, Jakovljevic DG, MacGowan GA, Anstee QM, Day CP, Taylor R, Trenell MI. Cardiac function improves following high intensity intermittent exercise in adults with non-alcoholic fatty liver disease. In: Diabetes UK Annual Professional Conference. 2013, Manchester, UK: Diabetes UK.
  • Whitehead A, Patman GL, Cornell L, Televantou D, Curtin N, Day CP, Burt AD, Piguet AC, Dufour JF, Anstee QM, Reeves HL, FLIP Investigators FP7-2007-2013. A Role for DNA Repair Protein Kinase (DNA-PK) in the Progression of Simple Steatosis to Steatohepatitis (NASH)?. In: 48th Annual meeting of the European Association for the Study of the Liver. 2013, Amsterdam, The Netherlands: Elsevier Science BV.
  • Anstee QM, Darlay R, Leathart J, Liu YL, Tordjman J, Clement K, Aithal G, Valenti L, Van Gaal L, Stickel F, Alison M, Romero-Gomez M, Andrade R, Reeves H, Bedossa P, Pihlajamaki J, Kotronen A, Yki-Jarvinen H, Chalasani N, Kleiner DE, Rotter J, Burt A, Ratziu V, Cordell HJ, Daly AK, Day CP, FLIP Fatty Liver Inhibition, NASH CRN Investigators. A candidate-gene approach to validation of genetic modifier associations using a large cohort with histologically characterised non-alcoholic fatty liver disease. In: The International Liver Congress 2013 – 48th Annual meeting of the European Association for the Study of the Liver. 2013, Amsterdam: Elsevier BV.
  • McPherson S, Griffiths L, Hardy T, Henderson E, Burt A, Day C, Anstee QM. The FIB-4 score reliability excludes advanced fibrosis in a diabetic cohort with NAFLD. In: 47th Annual Meeting of the European Association for the Study of the Liver (EASL). 2012, Barcelona, Spain: Elsevier BV.
  • Petts G, Dhar A, Kudo H, Sadiq F, Anstee QM, Kallis YN, Dorling A, Goldin R, Thursz MR. Targeted inhibition of Tissue Factor suppresses hepatic fibrosis in CCL4 treated mice. In: 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). 2012, Boston, Massachusetts, USA: John Wiley & Sons, Inc.
  • Petts G, Dhar A, Kudo H, Sadiq F, Anstee QM, Kallis Y, Dorling A, Goldin R, Thursz M. Targeted inhibition of tissue factor and thrombin on CD31 expressing cells supresses hepatic fibrosis in CCL4 treated mice. In: 47th Annual Meeting of the European Association for the Study of the Liver (EASL). 2012, Barcelona, Spain: Elsevier BV.
  • Petts G, Dhar A, Kudo H, Sadiq F, Anstee Q, Kallis Y, Dorling A, Goldin R, Thursz M. Targeted inhibition of tissue factor and thrombin on CD31 expressing cells suppresses hepatic fibrosis in CCl4 treated mice. In: Digestive Disorders Federation Meeting. 2012, Liverpool, UK: BMJ Group.
  • Patman G, Hui KY, Anstee QM, Reeves HL. Oxidative stress induces alternative splicing and nuclear translocation of kruppel like factor 6. In: Digestive Disorders Federation Meeting. 2012, Liverpool, UK: BMJ Group.
  • Cobbold JFL, Peake CM, Anstee QM, Yee MS, Thursz MR. Measuring the effectiveness of a multidisciplinary non-alcoholic fatty liver disease clinic. In: 47th Annual Meeting of the European Association for the Study of the Liver (EASL). 2012, Barcelona, Spain: Elsevier BV.
  • Patman GL, Hui KY, Anstee QM, Reeves HL. Kruppel-like factor 6 splice variant 3 (KLF6-SV3) - The redox sensitive splice variant of KLF6 expressed in non-alcoholic steatohepatitis (NASH). In: 47th Annual Meeting of the European Association for the Study of the Liver (EASL). 2012, Barcelona, Spain: Elsevier BV.
  • Possamai LA, Harrison M, Cox RD, Williams R, Anstee QM, Thursz MR, Cox IJ. H-1-NMR metabolic profiling in germ-free and conventionally housed mouse models of acetaminophen-induced hepatotoxicity. In: 47th Annual Meeting of the European Association for the Study of the Liver (EASL). 2012, Barcelona, Spain: Elsevier BV.
  • Anstee QM, Darlay R, Leathart JB, Clement J, Clement K, Aithal GP, Valenti L, Van Gaal L, Stickel F, Allison ME, Romero-Gomez M, Andrade RJ, Reeves H, Pihlajamaki J, Bedossa P, Kotronen A, Yki-Jarvinen H, Chalasani NP, Kleiner DE, Rotter J, Burt AD, Ratziu V, Cordell HJ, Daly AK, Day CP. Genome-Wide Association Analysis Confirms Importance of PNPLA3 and Identifies Novel Variants Associated With Histologically Progressive Steatohepatitis in NAFLD. In: 63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD). 2012, Boston, Massachusetts, USA: John Wiley & Sons, Inc.
  • Dhar A, Anstee QM, Sadiq F, Levene A, Cobbold J, Petts G, Taylor-Robinson S, Goldin R, Thursz MR. A role for anticoagulation in fibrogenesis: Supression of human hepatic stellate cell contractility and liver fibrosis in vitro and vivo. In: 47th Annual Meeting of the European Association for the Study of the Liver (EASL). 2012, Barcelona, Spain: Elsevier BV.
  • Concas D, Wu B, Kudo H, Levene A, Thomas HC, Goldin RD, Thursz MR, Anstee QM. Vanin-1 activity modulates the steatosis-steatohepatitis transition in progressive non-alcoholic steatohepatitis. In: Journal of Hepatology: 46th Annual Meeting of the European Association for the Study of the Liver (EASL). 2011, Berlin, Germany: Elsevier BV.
  • Patman GL, Anstee Q, Reeves HL. Hepatocellular Carcinoma in NASH: Is there a biological Rationale?. In: 9th Meeting of Therapy in Liver Diseases. 2011, Barcelona, Spain.
  • McPherson S, Anstee QM, Henderson E, Burt AD, Day CP. Are simple non-invasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels?. In: Hepatology: 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). 2011, San Francisco, California, USA: John Wiley & Sons, Inc.
  • Levene A, Kudo H, Thursz M, Anstee QM, Goldin RD. Activating Autophagocytosis Decreases Fat Within the Liver. In: Journal of Pathology: 199th Scientific Meeting of the Pathological Society of Great Britain and Ireland. 2011, Cambridge, UK: John Wiley & Sons Ltd.
  • Anstee QM, Concas D, Wu B, Potter P, Cox R, Kudo H, Levene A, Goldin RD, Thursz MR, Thomas HC. A novel mouse model of hepatic glycogen storage disease Type 3 identified using a phenotype-driven ethyl-nitrosourea (ENU) mutagensis screen. In: Journal of Hepatology: 46th Annual Meeting of the European Association for the Study of the Liver (EASL). 2011, Berlin, Germany: Elsevier BV.
  • Anstee QM, Possamai LA, Concas D, Wu B, Hassett C, Cox RD, Thomas HC, Thursz MR. Novel quantitative trait locus for acetaminophen-induced hepatotoxicty identified on chromosome 18. In: 45th Annual Meeting of the European Association for the Study of the Liver. 2010, Vienna, Austria: Journal of Hepatology: Elsevier BV.
  • Levene AP, Kudo H, Thursz MR, Anstee QM, Goldin RD. Is oil red-O and digital image analysis the gold standard for quantifying steatosis in the liver?. In: 45th Annual Meeting of the European Association for the Study of the Liver. 2010, Vienna, Austria: Journal of Hepatology: Elsevier BV.
  • Dhar A, Anstee QM, Kudo H, Goldin R, Thursz MR. Coagulation proteins in acute liver injury: a role in initiation and propagation. In: 45th Annual Meeting of the European Association for the Study of the Liver. 2010, Vienna, Austria: Journal of Hepatology: Elsevier BV.
  • Matthews HC, Concas D, Kudo H, Anstee QM, Thomas H, Cox R, Goldin RD, Thursz MR. Cell surface pantetheinase, Vanin-1, increases oxidative damage in acetaminophen-induced liver injury via a reduction in glutathione. In: 45th Annual Meeting of the European Association for the Study of the Liver. 2010, Vienna, Austria: Journal of Hepatology: Elsevier BV.
  • Cobbold JF, Anstee QM, Taylor Robinson SD. The importance of fatty liver disease in clinical practice. In: Annual Meeting of the Nutrition Society and BAPEN. 2009, Cardiff International Arena, Cardiff: Proceedings of the Nutrition Society: Cambridge University Press.
  • Anstee QM, Hoa NT, Sauvage V, Concas D, Levene AP, Thomas H, Thursz MR, Elson D, Goldin R. Autofluorescence: modelling a tool for assessment of steatotic marginal grafts in liver transplantation. In: 60th Annual Meeting of the American Association for the Study of Liver Diseases. 2009, Boston, Massachusetts: Hepatology: John Wiley & Sons, Inc.
  • Knapp S, Hosie AM, Anstee QM, Thomos P, Mortensen M, Martinez A, Tymowska-Lalanne Z, McQuillin A, Gurling HM, Morgan MY, Kuo YT, Herlihy A, Bell JD, Robinson I, Fisher E, Brown S, Stephens D, Smart TG, Thomas HC. Identification of a model of alcohol preference and its similarity to human alcoholism. In: 59th Annual Meeting of the American Association for the Study of Liver Diseases. 2008, San Francisco, California: Hepatology: John Wiley & Sons, Inc.
  • Anstee QM, Goldsworthy M, Goldin R, Thomas HC, Cox R, Thursz M. Microarray analysis demonstrates insulin resistance is central to NASH pathogenesis in the IGT/6 model and suggests a role for CEACAM-1 in disease pathogenesis. In: 42nd Annual Meeting of the European Association for the Study of the Liver. 2007, Barcelona, Spain: Journal of Hepatology: Elsevier BV.
  • Cobbold JF, Chinthaplli S, Anstee QM, Goldin RD, Cox R, Thursz MR, Thomas HC, Taylor-Robinson SD, Cox IJ. Dietary constituents in mice are reflected in the hepatic lipid profile as detected by carbon-13 magic angle spinning magnetic resonance spectroscopy. In: 58th Annual Meeting of the American Association for the Study of Liver Diseases. 2007, Boston, Massachusetts: Hepatology: John Wiley & Sons, Inc.
  • Cobbold JF, Anstee QM, Goldin RD, Cox RD, Thursz MR, Thomas HC, Taylor-Robinson SD, Cox IJ. Can disease progression in non-alcoholic fatty liver disease be predicted by metabolic biomarkers of lipid accumulation and peroxidation?. In: 42nd Annual Meeting of the European Association for the Study of the Liver. 2007, Barcelona, Spain: Journal of Hepatology: Elsevier BV.
  • Anstee QM, Goldsworthy M, Goldin R, Thomas HC, Cox RD, Thursz M. Microarray principal components analysis demonstrates expression of Vanin-1 is a strong determinant of NASH pathogenesis in the IGT/6 model. In: 57th Annual Meeting of the American Association for the Study of Liver Diseases. 2006, Boston, Massachusetts: Hepatology: John Wiley & Sons, Inc.
  • Anstee QM, Wright M, Goldin R, Thomas HC, Thursz M. The factor V Leiden mutation accelerates disease progression in a mouse model of hepatic fibrosis induced by chronic carbon tetrachloride exposure. In: 55th Annual Meeting of the American Association for the Study of Liver Diseases. 2004, Boston, Massachusetts: Hepatology: John Wiley & Sons, Inc.
  • Anstee QM, Goldsworthy M, Haynes A, Hugill A, Goldin R, Thursz M, Cox RD, Thomas H. A novel murine model of non-alcoholic steatohepatitis generated using a sensitised ENU mutagenesis screen. In: 54th Annual Meeting of the American Association for the Study of Liver Diseases. 2003, Boston, Massachusetts: Hepatology: John Wiley & Sons, Inc.

• Editorials

  • Ratziu V, Rinella M, Beuers U, Loomba R, Anstee QM, Harrison S, Francque S, Sanyal A, Newsome PN, Younossi Z. The times they are a-changin' (for NAFLD as well). Journal of Hepatology 2020, 73(6), 1307-1309.
  • Ravaioli F, Anstee QM. Editorial: collagen proportionate area as a prognostic indicator in NAFLD. Alimentary Pharmacology and Therapeutics 2019, 49(11), 1452-1454.
  • Boyle M, Anstee QM. Editorial: hepatocellular carcinoma in non-cirrhotic NASH - a troubling reality. Alimentary Pharmacology and Therapeutics 2018, 48(9), 1021-1023.
  • Patel YA, Imperial JC, Muir AJ, Anstee QM, DeBrota D, Dimick-Santos L, Filozof C, Mehta R, Sanyal AJ, Schabel E, Neuschwander-Tetri BA, Miller V, Anstee QM, Bangma S, Baxter M, Boulos S, Burgess G, Chakravarthy M, Christian R, Coombs A, DeBrota D, Dimick-Santos L, Filozof C, Gannedahl G, Herrmann R, Hum D, Imperial J, Kendrick S, MacConell L, Megnien S, Mehta R, Miller V, Muir A, Neuschwander-Tetri BA, Patel Y, Peres D, Rossi S, Sanyal A, Schabel E, Shapiro D, St Pierre T, Zemel M. Baseline Parameters in Clinical Trials for Nonalcoholic Steatohepatitis: Recommendations From the Liver Forum. Gastroenterology 2017, 153(3), 621-625.e7.
  • McPherson S, Anstee QM. Changing Epidemiology of Chronic Liver Disease Among Ethnic Groups in the United States. Hepatology 2016, 64(6), 1843-1846.
  • Adams LA, Anstee QM. A fatty liver leads to a broken heart?. Journal of Hepatology 2016, 65(1), 14-16.
  • Kahali B, Liu YL, Daly AK, Day CP, Anstee QM, Speliotes EK. TM6SF2: Catch-22 in the Fight Against Nonalcoholic Fatty Liver Disease and Cardiovascular Disease?. Gastroenterology 2015, 148(4), 679-684.
  • Day CP, Anstee QM. Nonalcoholic Fatty Liver Disease: Foreword. Seminars in Liver Disease 2015, 35(3), 203-205.
  • Anstee QM. Animal models in nonalcoholic steatohepatitis research: utility and clinical translation. Liver International 2011, 31(4), 440-442.

• Letters

  • Vali Y, Anstee QM, Bossuyt PM. Response to: Precision in Diagnosis of Liver Fibrosis in MASLD: Machine Learning Based Scores May Be More Accurate Than Conventional NITs. Liver International 2025, 45(5), e70077.
  • Noureddin M, Truong E, Mayo R, Martinez-Arranz I, Minchole I, Banales JM, Arrese M, Cusi K, Arias-Loste MT, Bruha R, Romero-Gomez M, Iruzubieta P, Aller R, Ampuero J, Calleja JL, Ibanez-Samaniego L, Aspichueta P, Marin-Duce A, Kushner T, Ortiz P, Harrison SA, Anstee QM, Crespo J, Mato JM, Sanyal AJ. Letter to the Editor: Serum Identification of At-Risk MASH: The Metabolomics-Advanced Steatohepatitis Fibrosis Score (MASEF). Hepatology 2025, 81(1), E12-E16.
  • McPherson S, Dyson JK, Jopson L, Masson S, Patel P, Anstee QM. Letter: Beyond advanced fibrosis—The critical need for assessing NITs performance in identifying F2-F3 fibrosis. Authors' reply. Alimentary Pharmacology and Therapeutics 2024, 60(7), 976-977.
  • McPherson S, Dyson JK, Jopson L, Masson S, Patel P, Anstee QM. Letter: Algorithmic NIT approaches to identify advanced liver fibrosis in patients with MASLD: Authors' reply. Alimentary Pharmacology and Therapeutics 2024, 60(7), 980-981.
  • Scragg J, Charman SJ, van Hees VT, Avery L, Taylor GS, Anstee QM, McPherson S, Cassidy S, Hallsworth K. Physical Activity, Inactivity and Sleep in Patients with Significant Non-Alcoholic Fatty Liver Disease. American Journal of the Medical Sciences 2022, 363(1), 80-83.
  • Brandman D, Boyle M, McPherson S, Van Natta ML, Sanyal AJ, Kowdley K, Neuschwander-Tetri B, Chalasani N, Abdelmalek MF, Terrault NA, McCullough A, Bettencourt R, Caussy C, Kleiner DE, Behling C, Tonascia J, Anstee QM, Loomba R. Letter: non-invasive prediction models to exclude cirrhosis in NAFLD—not everyone fits the mould. Authors' reply. Alimentary Pharmacology and Therapeutics 2022, 56(1), 182-183.
  • Vali Y, Anstee QM, Bossuyt PM. Reply to: “Errors in modeling misrepresent the utility of the enhanced liver fibrosis test in the management of non-alcoholic fatty liver disease”. Journal of Hepatology 2020, 73(6), 1582-1583.
  • Lazarus JV, Cortez-Pinto H, Anstee QM. Reply to: “Caveats for the implementation of global strategies against non-alcoholic fatty liver disease”. Journal of Hepatology 2020, 73(1), 221-222.
  • Daly AK, Day CP, Liu YL, Anstee QM. TM6SF2 as a Genetic Risk Factor for Fibrosis. Hepatology 2015, 62(4), 1321-1321.
  • Anstee QM, Liu YL, Day CP, Reeves HL. Reply to: HCC and liver disease risk in homozygous PNPLA3 p.I148M carriers approach monogenic inheritance. Journal of Hepatology 2015, 62(4), 982-983.
  • Anstee QM, Jaques B, Hudson M, Reeves HL. Reply to "Hepatocellular carcinoma and the Newcastle-upon-Tyne area". Journal of Hepatology 2014, 60(6), 1330-1331.
  • Anty R, Anstee QM, Gual P, Tran A. Prophylaxis of bacterial infections in cirrhosis: Is an optimal 25-OH vitamin D level required?. Journal of Hepatology 2014, 61(4), 965-966.
  • Levene AP, Kudo H, Thursz MR, Anstee QM, Goldin RD. Is oil red-O staining and digital image analysis the gold standard for quantifying steatosis in the liver?. Hepatology 2010, 51(5), 1859-1859.

• Notes

  • Rinella ME, Hartman ML, Shinde S, Schapiro D, Higgins V, Anstee QM. Variance Between Clinical Guidance and Real-world Management of Metabolic Dysfunction-associated Steatotic Liver Disease in the United States. Clinical Gastroenterology and Hepatology 2025, 23(2), 374-376.e3.
  • Pericas JM, Anstee QM, Augustin S, Bataller R, Berzigotti A, Ciudin A, Francque S, Abraldes JG, Hernandez-Gea V, Pons M, Reiberger T, Rowe IA, Rydqvist P, Schabel E, Tacke F, Tsochatzis EA, Genesca J. Correction to: A roadmap for clinical trials in MASH-related compensated cirrhosis (Nature Reviews Gastroenterology & Hepatology, (2024), 10.1038/s41575-024-00955-8). Nature Reviews Gastroenterology and Hepatology 2024, 21, 824.
  • Pfister D, Nunez N, Sinha A, Weiner A, Deczkowska A, Pinter M, Govaere O, Muller F, Anstee QM, Entgleitner T, Rad R, Pinyol R, Torrecilla S, Dudek M, Knolle P, Weber A, Lengenhagger D, Llovet JM, Amit I, Meissner F, Becher B, Heikenwalder M. Erratum: Adverse effects of PD-1 targeted immunotherapy in NAFLD-triggered HCC. Zeitschrift fur Gastroenterologie 2020, 58(3), e71-e71.
  • Shalapour S, Lin X-J, Bastian IN, Brain J, Burt AD, Aksenov AA, Vrbanac AF, Li W, Perkins A, Matsutani T, Zhong Z, Dhar D, Navas-Molina JA, Xu J, Loomba R, Downes M, Yu RT, Evans RM, Dorrestein PC, Knight R, Benner C, Anstee QM, Karin M. Erratum to: Inflammation-induced IgA⁺ cells dismantle anti-liver cancer immunity (Nature, (2017), 551, 7680, (340-345), 10.1038/nature24302). Nature 2018, 561(7721), E1-E1.
  • Shalapour S, Lin XJ, Bastian IN, Brain J, Burt AD, Aksenov AA, Vrbanac AF, Li W, Perkins A, Matsutani T, Zhong Z, Dhar D, Navas-Molina JA, Xu J, Loomba R, Downes M, Yu RT, Evans RM, Dorrestein PC, Knight R, Benner C, Anstee QM, Karin M. Author correction: Inflammation-induced IgA⁺ cells dismantle anti-liver cancer immunity. Nature 2018, 561, E1.

• Reviews

  • de Zawadzki A, Leeming DJ, Sanyal AJ, Anstee QM, Schattenberg JM, Friedman SL, Schuppan D, Karsdal MA. Hot and cold fibrosis: The role of serum biomarkers to assess immune mechanisms and ECM-cell interactions in human fibrosis. Journal of Hepatology 2025, epub ahead of print.
  • Mayorca-Guiliani AE, Leeming DJ, Henriksen K, Mortensen JH, Nielsen SH, Anstee QM, Sanyal AJ, Karsdal MA, Schuppan D. ECM formation and degradation during fibrosis, repair, and regeneration. NPJ Metabolic Health and Disease 2025, 3(1), 25.
  • Tincopa MA, Anstee QM, Loomba R. New and emerging treatments for metabolic dysfunction-associated steatohepatitis. Cell Metabolism 2024, 36(5), 912-926.
  • Younossi ZM, Wong G, Anstee QM, Henry L. The Global Burden of Liver Disease. Clinical Gastroenterology and Hepatology 2023, 21(8), 1978-1991.
  • Pericas JM, DiProspero NA, Anstee QM, Kjaer MS, Koenig F, Sena E, Pais R, Manzano R, Genesca J, Tacke F, Ratziu V, DiProspero NA, Ratziu V, Pericas JM, Kjaer MS, Anstee QM, Tacke F, Mesenbrinck P, Mesenbrinck P, Rivera-Esteban J, Rivera-Esteban J, Koenig F, Sena E, Manzano R, Genesca J, Pais R, Kara L, Meyer E, Duca A, Kline T, Aaes-Jorgensen A, Balthaus T, de Preville N, Zhang L, Capuano G, Morello S, Mielke T, Penna SH, Posch M. Review article: The need for more efficient and patient-oriented drug development pathways in NASH—setting the scene for platform trials. Alimentary Pharmacology and Therapeutics 2023, 57(9), 948-961.
  • Pericas JM, Tacke F, Anstee QM, Di Prospero NA, Kjaer MS, Mesenbrink P, Koenig F, Genesca J, Ratziu V. Platform trials to overcome major shortcomings of traditional clinical trials in non-alcoholic steatohepatitis? Pros and cons. Journal of Hepatology 2023, 78(2), 442-447.
  • Rasmussen DGK, Anstee QM, Torstenson R, Golding B, Patterson SD, Brass C, Thakker P, Harrison S, Billin AN, Schuppan D, Dufour J-F, Andersson A, Wigley I, Shumbayawonda E, Dennis A, Schoelch C, Ratziu V, Yunis C, Bossuyt P, Karsdal MA. NAFLD and NASH biomarker qualification in the LITMUS consortium – Lessons learned. Journal of Hepatology 2023, 78, 852-865.
  • Jarvis H, O'Keefe H, Craig D, Stow D, Hanratty B, Anstee QM. Does moderate alcohol consumption accelerate the progression of liver disease in NAFLD? A systematic review and narrative synthesis. BMJ Open 2022, 12(1), e049767.
  • Mak AL, Lee J, van Dijk A-M, Vali Y, Aithal GP, Schattenberg JM, Anstee QM, Brosnan MJ, Zafarmand MH, Ramsoekh D, Harrison SA, Nieuwdorp M, Bossuyt PM, Holleboom AG. Systematic review with meta-analysis: Diagnostic accuracy of Pro-C3 for hepatic fibrosis in patients with non-alcoholic fatty liver disease. Biomedicines 2021, 9(12), 1920.
  • van Dijk A-M, Vali Y, Mak AL, Lee J, Tushuizen ME, Zafarmand MH, Anstee QM, Brosnan MJ, Nieuwdorp M, Bossuyt PM, Holleboom AG. Systematic review with meta-analyses: Diagnostic accuracy of fibrometer tests in patients with non-alcoholic fatty liver disease. Journal of Clinical Medicine 2021, 10(13), 2910.
  • Masoodi M, Gastaldelli A, Hyotylainen T, Arretxe E, Alonso C, Gaggini M, Brosnan J, Anstee QM, Millet O, Ortiz P, Mato JM, Dufour J-F, Oresic M. Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests. Nature Reviews Gastroenterology and Hepatology 2021, 18, 835-856.
  • Schattenberg JM, Anstee QM, Caussy C, Bugianesi E, Popovic B. Differences between current clinical guidelines for screening, diagnosis and management of nonalcoholic fatty liver disease and real-world practice: a targeted literature review. Expert Review of Gastroenterology and Hepatology 2021, 15(11), 1253-1266.
  • Rinella ME, Tacke F, Sanyal AJ, Anstee QM. Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD. Journal of Hepatology 2019, 71(4), 823-833.
  • Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M. From NASH to HCC: current concepts and future challenges. Nature Reviews Gastroenterology and Hepatology 2019, 16, 411-428.
  • Scott EJ, Anstee QM. The genetics of alcoholic liver disease and non-alcoholic steatohepatitis. Clinical Medicine 2018, 18(Suppl. 2), s54-s59.
  • Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, George J, Bugianesi E. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. Nature Reviews Gastroenterology and Hepatology 2018, 15(1), 11-20.
  • Scott E, Anstee QM. Genetics of alcoholic liver disease and non-alcoholic steatohepatitis. Clinical Medicine 2018, 18, s54-s59.
  • Noureddin M, Anstee QM, Loomba R. Review article: emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis. Alimentary Pharmacology and Therapeutics 2016, 43(11), 1109-1123.
  • Hardy T, Oakley F, Anstee QM, Day CP. Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum. Annual Review of Pathology: Mechanisms of Disease 2016, 11, 451-496.
  • Anstee QM, Day CP. The Genetics of Nonalcoholic Fatty Liver Disease: Spotlight on PNPLA3 and TM6SF2. Seminars in Liver Disease 2015, 35(3), 270-290.
  • Dyson JK, Anstee QM, McPherson S. Non-alcoholic fatty liver disease: a practical approach to treatment. Postgraduate Medical Journal 2015, 91(1072), 92-101.
  • Anstee QM, Daly AK, Day CP. Genetics of Alcoholic Liver Disease. Seminars in Liver Disease 2015, 35(4), 361-374.
  • Rowell RJ, Anstee QM. An overview of the genetics, mechanisms and management of NAFLD and ALD. Clinical Medicine, Journal of the Royal College of Physicians of London 2015, 15(6), s77-s82.
  • Rowell RJ, Anstee QM. An overview of the genetics, mechanisms and management of NAFLD and ALD. Clinical medicine 2015, 15(6), s77-s82.
  • Dyson JK, McPherson S, Anstee QM. Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. Postgraduate Medical Journal 2014, 90(1063), 254-266.
  • Anstee QM, Day CP. The genetics of NAFLD. Nature Reviews Gastroenterology and Hepatology 2013, 10(11), 645-655.
  • Dyson JK, McPherson S, Anstee QM. Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. Journal of Clinical Pathology 2013, 66(12), 1033-1045.
  • Dongiovanni P, Anstee QM, Valenti L. Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment. Current Pharmaceutical Design 2013, 19(29), 5219-5238.
  • Anstee QM, Day CP. S-adenosylmethionine (SAMe) therapy in liver disease: A review of current evidence and clinical utility. Journal of Hepatology 2012, 57(5), 1097-1109.
  • Tripodi A, Anstee QM, Sogaard KK, Primignani M, Valla DC. Hypercoagulability in cirrhosis: causes and consequences. Journal of Thrombosis and Haemostasis 2011, 9(9), 1713-1723.
  • Anstee QM, Daly AK, Day CP. Genetics of alcoholic liver disease and nonalcoholic fatty liver disease. Seminars in Liver Disease 2011, 31(2), 128-146.
  • Anstee QM, Daly AK, Day CP. Genetic modifiers of non-alcoholic fatty liver disease progression. Biochimica et Biophysica Acta: Molecular Basis of Disease 2011, 1812(11), 1557-1566.